TWI663966B - Physiological supplies - Google Patents

Abstract

The physiological article (10) of the present invention includes a front sheet (20) on the skin contact surface side, a back sheet (30) on the non-skin contact surface side, and an absorber (40) sandwiched therebetween. . A blood cell agglutinating agent region containing a blood cell agglutinating agent and a liquid film cleaving agent region containing a liquid film cleaving agent are arranged on the absorber (40) or closer to the skin abutting surface side than the absorber (40). For example, the liquid film-containing cracking agent region may be provided on the front sheet (20), and the blood cell agglutinating agent-containing region may be provided on the core material (42) constituting the absorber (40).

Description

Physiological supplies

The present invention relates to a physiological article for absorbing menstrual blood.

Women's menstrual blood or vaginal discharge are treated with physiological products. Physiological products usually have a structure in which an absorbent body capable of absorbing and retaining excreta such as menstrual blood is provided between a front sheet on the skin contacting surface side and a back sheet on the non-skin contacting surface side.

Techniques are known in which cationic polymer materials are applied to such physiological products to improve various properties. For example, Patent Document 1 describes a personal care absorbent article such as a sanitary napkin or a tampon which is made of a porous non-woven mesh material treated with a treatment agent that dissolves red blood cells in the blood, or dissolves them. In the same literature, as the treating agent, a polycationic material which is a polymer having a strong positive charge is used. The treatment agent agglutinates or dissolves red blood cells in the blood when the blood enters or passes through the absorbent article.

Further, Patent Document 2 discloses that the top sheet contains a blood modifier in order to improve the skin feel of the top sheet after absorbing menstrual blood. The blood modifier can reduce the viscosity and surface tension of the blood, stabilize the blood cells and prevent the formation of a coin string structure, so that the absorber can easily absorb menstrual blood.

[Prior technical literature] [Patent Literature]

Patent Document 1: Japanese Patent Publication No. 2002-528232

Patent Document 2: Japanese Patent Laid-Open No. 2013-063245

The present invention provides a physiological article having a front sheet on the skin contact surface side, a back sheet on the non-skin contact surface side, and an absorber sandwiched therebetween. The physiological article of the present invention is provided with a blood cell agglutinating agent region containing a blood cell agglutinating agent and a liquid film cleaving agent region containing a liquid film cleaving agent on the absorbent body or on the skin abutting surface side than the absorber.

The present invention also provides a physiological article including a front sheet on the skin contact surface side, a back sheet on the non-skin contact surface side, and an absorber sandwiched therebetween. The physiological article of the present invention is provided with a cationic polymer-containing region containing a cationic polymer and a compound-containing region containing the following compound C1 on the absorbent body or on the skin abutting surface side than the absorbent body.

[Compound C1]

Compounds with an expansion coefficient of 15 mN / m or more for liquids with a surface tension of 50 mN / m.

The present invention also provides a physiological article including a front sheet on the skin contact surface side, a back sheet on the non-skin contact surface side, and an absorber sandwiched therebetween. The physiological article of the present invention includes a cationic polymer-containing region containing a cationic polymer and a compound-containing region containing the following compound C2 on the absorbent body or on the skin abutting surface side than the absorbent body.

[Compound C2]

Compounds whose expansion coefficient is greater than 0 mN / m for liquids with a surface tension of 50 mN / m, and whose interfacial tension is 20 mN / m or less for liquids with a surface tension of 50 mN / m.

1‧‧‧ menstrual blood

2‧‧‧ Liquid composition

3‧‧‧ Non-liquid ingredients

4‧‧‧ Super Absorbent Polymer

5‧‧‧ capsule

6‧‧‧ agglomerates

7‧‧‧ fiber

8‧‧‧ liquid film

9‧‧‧ Liquid film cracking agent

10‧‧‧Menstruation

X‧‧‧Vertical

Y‧‧‧Horizontal

20‧‧‧Front sheet

20A‧‧‧Skin contact surface (first side)

20B‧‧‧ Non-skin contact surface (second side)

21‧‧‧ convex

22‧‧‧ Recess

30‧‧‧Back sheet

40‧‧‧ Absorber

41‧‧‧ Absorbent core material

42‧‧‧Packaging Chips

50‧‧‧ end seal

60‧‧‧Leakproof trench

70‧‧‧ side sheet

FIG. 1 is a schematic diagram showing a mechanism for absorbing menstrual blood in the physiological article of the present invention.

2 (a) and 2 (b) are schematic diagrams showing a mechanism for absorbing menstrual blood in a conventional physiological article.

Fig. 3 is a schematic view showing a liquid film formed in a gap between fibers of a non-woven fabric.

FIG. 4 is an explanatory diagram of a liquid film cracking process realized by using a liquid film cracking agent according to the present invention, (A1) to (A4) are side views of a pattern of gradually cracked liquid film, and (B1) to (B4) are A perspective view of the pattern seen above the same liquid film.

FIG. 5 is a plan view schematically showing a skin contact surface of a menstrual napkin according to an embodiment of the physiological article of the present invention.

Fig. 6 is a cross-sectional view schematically showing a cross-section taken along a line I-I in Fig. 5.

FIG. 7 is a perspective view showing only the front sheet of the menstrual napkin shown in FIG. 5.

It is known that the rate or amount of water absorbed by a superabsorbent polymer varies depending on the kind of water. For example, comparing the case where the superabsorbent polymer absorbs physiological saline and the blood, the absorption rate of blood is slower and the amount of absorption is lower than that of physiological saline. Therefore, in order to improve the performance of physiological products, it is important to improve the various absorption properties of the superabsorbent polymer to the blood. Patent Literature 1 or Patent Literature 2 discloses a blood-modifying agent, but it is insufficient for improving the absorption performance of a superabsorbent polymer and reducing the amount of liquid returned from a physiological product.

In addition, the front sheet of the physiological product on the skin abutting surface side is usually white in the unused state, so the user of the physiological product observes the removed physiological product from the front sheet side, and the surface is white according to the surface. And feel relieved about absorption performance. Therefore, the surface whiteness after use is required to be more excellent. There is no description of surface whiteness in Patent Literature 1 or Patent Literature 2. In other words, no research has been carried out on which part of the physiological article the reformed blood should be kept in.

The present inventors and others have conducted various studies with the aim of increasing the absorption capacity of menstrual blood in physiological products. As a result, it has been found that coating red blood cells contained in menstrual blood on the surface of the superabsorbent polymer will cause the superabsorbent polymer to affect menstrual blood. The decrease in the absorption performance (absorption speed, absorption amount) leads to an increase in the amount of liquid return of physiological articles. In order to prevent this problem, the following insights have been obtained: the placement of water-soluble cationic polymer pairs having the ability to agglutinate red blood cells is reduced in the position in physiological products that can first contact the menstrual blood excreted by the user compared to the superabsorbent polymer The liquid return amount of physiological products is effective. However, it can be seen that when a red blood cell agglomerate is formed on the front sheet side of a physiological article by a water-soluble cationic polymer, there is room for improvement in the appearance seen from the front sheet side after use.

In addition, the present inventors conducted various studies for the purpose of improving the whiteness of the surface of physiological articles after use. As a result, it was found that menstrual blood in a non-woven fabric such as a front sheet forms a liquid film between fibers and stays there. This is after use. An important reason for the decrease in surface whiteness. In order to prevent this problem, it has been found that a liquid film cleaving agent which is disposed on the front sheet and the like and has the ability to crack the liquid film with respect to menstrual blood excreted by the user is effective for improving the whiteness of the surface of a physiological article after use. It can be seen that the liquid film in the front sheet disappears and also has the effect of reducing the amount of liquid returned, but there is still room for improvement in order to achieve further reduction.

Therefore, the present invention relates to providing a physiological product which reduces the amount of liquid return and has excellent surface whiteness after use.

Hereinafter, the present invention will be described based on its preferred embodiments. The physiological article of the present invention generally has a liquid-retaining absorbent. The absorbent body is preferably a highly absorbent polymer containing a hydrogel material capable of absorbing and retaining moisture. A liquid-permeable front sheet can be arranged on the skin abutment surface side of the user in the absorbent body. In addition, the back can be arranged on the non-skin contact surface side of the absorber. Noodle sheet. In the present specification, the "skin abutment surface" refers to the surface of the physiological article or its constituent member that faces the skin side of the user when the physiological article is used, that is, the surface that is relatively closer to the skin side of the user. In this specification, the "non-skin contact surface" refers to the surface of the physiological article or its constituent member that faces the side opposite to the user's skin side when the physiological article is used, that is, the side that faces clothing such as shorts, in other words, It is the side farther from the user's skin than the skin abutment side.

The physiological article of the present invention has a hemagglutinating agent-containing region containing a hemagglutinating agent as described in detail below and a liquid film-cracking agent-containing region containing a liquid film cleavage agent described in detail below. Hemagglutination agent is used to increase the absorption of superabsorbent polymer, and liquid film cleaving agent is used to control the diffusion of liquid in the absorbent body. Thus, the present invention provides a physiological product that reduces the amount of liquid returned and has excellent surface whiteness after use. .

(Hemagglutination agent)

Regarding the reason that the rate or amount of water absorbed by the superabsorbent polymer varies depending on the type of water, the present inventors have conducted various studies and found out the facts described below. Blood is roughly divided into liquid components such as plasma and non-liquid components such as red blood cells, and components absorbed by the superabsorbent polymer are liquid components such as plasma. As shown in FIG. 2 (a), if menstrual blood 1 contacts the superabsorbent polymer 4, only the liquid component 2 in the menstrual blood 1 is absorbed by the superabsorbent polymer 4, and the red blood cells as non-liquid component 3 are not highly absorbent. Polymer 4 absorbs. If the absorption of the liquid component 2 into the superabsorbent polymer 4 continues, as shown in FIG. 2 (b), the non-liquid component 3 not absorbed by the superabsorbent polymer 4 accumulates on the surface of the superabsorbent polymer 4. And a film 5 is formed. The formation of the film 5 prevents the liquid absorption of the superabsorbent polymer 4 and reduces the absorption rate. In addition, the formation of the film 5 also inhibits the swelling of the superabsorbent polymer 4 and decreases the amount of absorption.

Regarding a method for preventing the phenomenon shown in FIG. 2 (b) from occurring and preventing a decrease in absorption performance, As a result of various studies, the present inventors have determined that it is effective to aggregate red blood cells, which are the majority of non-liquid components in menstrual blood, as shown in FIG. 1 to generate agglomerates 6. By forming agglomerates 6 of red blood cells, it is difficult to form a film of the agglomerates 6 on the surface of the superabsorbent polymer 4, or even if a film of the agglomerates 6 is formed, there remains a liquid in the film that can pass through the liquid component 2. Space, it is difficult to hinder absorption of the liquid component 2. As a result, the superabsorbent polymer 4 can fully exhibit the original absorption performance. Thus, in order to further improve the absorption performance, the larger the particle size of the agglomerates of the red blood cells, the better, and the harder the agglomerates, the better.

If the blood cell agglutination agent is in contact with menstrual blood, which is a typical excrement, the blood cell agglutination agent is dissolved into the menstrual blood, and the anionic red blood cells contained in the menstrual blood are agglomerated to form a blood cell agglomerate. The hemagglutination produced by the hemagglutination effect is larger than that of red blood cells. Therefore, even if the hemagglutination is attached to a part of the surface of the superabsorbent polymer, it is unlikely that most of the surface of the superabsorbent polymer is agglutinated by the blood cells. Defects such as block coverage, so that the absorptive properties originally possessed by superabsorbent polymers can be stably exhibited.

As the blood cell agglutinating agent used in the physiological article of the present invention, one having the function of agglutinating red blood cells in the blood is used. The red blood cells agglutinated by the blood cell agglutination agent become a clot. Examples of the blood cell agglutinating agent include a fluid treating agent described in Japanese Patent Publication No. 2002-528232, or a blood gelling agent described in Japanese Patent Laid-Open No. 57-153648. According to the inventors' findings, Cationic polymers are useful as hemagglutinating agents. The reason is as follows. A red blood cell has a red blood cell membrane on its surface. The red blood cell membrane has a double-layered structure. The bilayer structure includes a red blood cell membrane skeleton as a lower layer and a lipid membrane as an upper layer. The lipid membrane exposed to the surface of red blood cells contains a protein called a blood group glycoprotein. Blood group glycoproteins have a sugar chain with an anionically charged sugar called sialic acid bonded at their ends. As a result, red blood cells can be treated as colloidal particles having an anion charge. When aggregating colloidal particles, an aggregating agent is generally used. considering Red blood cells are anionic colloidal particles. In terms of neutralizing the electric double layer of red blood cells, it is advantageous to use a cationic substance as an agglutinating agent. In addition, if the agglutinating agent has a polymer chain, the polymer chains of the agglutinating agent adsorbed on the surface of the red blood cells tend to entangle with each other, thereby promoting the aggregation of the red blood cells. Furthermore, when the agglutinating agent has a functional group, it is preferable that the aggregation of red blood cells is also promoted by the interaction between the functional groups. Utilizing a cationic polymer, it is possible to generate a clot of red blood cells in menstrual blood through the above-mentioned mechanism of action.

(Properties of forming agglomerates)

The blood cell agglutination agent used in the present invention functions to aggregate red blood cells in the blood and separate a blood clot and a plasma component.

Examples of the required hemagglutinating agent include those having the following properties.

That is, when 1000 ppm of the measurement sample agent is added to the simulated blood, at least two or more red blood cells are aggregated to form a clot while the blood fluidity is maintained.

The above-mentioned "state in which blood fluidity is maintained" means a state in which 10 g of simulated blood to which 1000 ppm of a measurement sample agent is added is placed in a spiral vial (manufactured by Maruemu Co., Ltd., product number "spiral tube No. 4" , The inside diameter of the mouth is 14.5mm, the diameter of the cylinder is 27mm, the total length is 55mm), when the spiral tube containing the simulated blood is turned 180 degrees, 60% of the simulated blood flows within 20 seconds. The "simulated blood" is a viscosity at 25 ° C measured using a B-type viscosity meter (manufactured by Toki Sangyo Co., Ltd., model TVB-10M, measurement conditions: rotor No. 19, 30 rpm, 60 seconds). Become a person who adjusts the blood cell and plasma ratio of defibrillated horse blood (manufactured by Nippon Bio-Test Laboratories Co., Ltd.) in a way of 8mPa · s.

Whether the above-mentioned "two or more red blood cells agglomerate to form a clot" is determined by the following method. That is, the simulated blood to which the 1000 ppm measurement sample was added was diluted 4000 times with physiological saline, and a laser diffraction / scattering type particle size distribution measuring device (Horiba Manufacturing Co., Ltd.) was used. Manufactured by Co., Ltd., Model: LA-950V2, Measurement conditions: Flow cytometry, Circulation speed 1, No ultrasonic wave) Laser diffraction scattering method, the average volume particle size measured at a temperature of 25 ° C When the value diameter is 10 μm or more corresponding to the size of an agglomerate formed by agglutination of two or more red blood cells, it is determined that “agglomeration of two or more red blood cells is formed to form an agglomerate”.

The hemagglutination agent used in the present invention is a single compound that meets the above-mentioned properties or a mixture of a plurality of single compounds that meets the above-mentioned properties, or a combination of a plurality of compounds that satisfies the above-mentioned properties (the ability to achieve red blood cells Agglutination) agent. That is, the so-called hemagglutination agent is defined as an agent that always has a hemagglutination effect based on the above definition. Therefore, the compound used in a physiological article is different from a hemagglutinating agent when it contains a third component that does not meet the above definition. In addition, the "single compound" here refers to a concept including compounds having the same compositional formula but different molecular weights due to different numbers of repeating units.

As the blood cell agglutinating agent, those described in International Publication No. 2016/093233 can be used arbitrarily.

The hemagglutination agent preferably has a blood agglutination speed of 0.75 mPa · s / s or less. Blood agglutination rate is a measure of the ability of a hemagglutinating agent to agglutinate blood to form a clot. A smaller value indicates a smaller size of the clot after a certain period of time. That is, if blood is agglutinated by a hemagglutination agent, when the size of the agglomerates generated by the agglutination is large after a certain period of time, there is a possibility that the agglomerates cause blockage of the constituent members of the physiological article and impair liquid permeability. In this case, by controlling the above-mentioned agglutination rate, the liquid permeability is not reduced due to the agglomerates, so that the absorption capacity of the superabsorbent polymer can be improved. As a result, the contradictory requirements for increasing the liquid permeability and the requirements for increasing the absorption capacity of the superabsorbent polymer can be satisfied at the same time. From this viewpoint, the agglomeration speed is more preferably 0.32 mPa · s / s or less, and still more preferably 0.15 mPa · s / s or less. The lower limit of the aggregation speed is preferably 0.001 mPa · s / s or more, and more preferably 0.01 mPa · s / s or more.

The agglutination rate is measured by the following method. The blood used for the measurement of the agglutination rate is the aforementioned suspected blood. Using a rheometer (manufactured by Thermo Fisher Scientific, Inc., HAAKE RheoStress 6000), 2 μL of physiological saline in which 5% of hemagglutination agent was dissolved in advance was dripped onto 200 μL of blood dispersed on a stage in advance, and a cone of 35 mmΦ was used. The viscosity of the plate (gradient 1 degree) was measured under the conditions of temperature: 30 degrees and shear rate: 10 ¹ (seconds ^-1 ). The viscosity change was measured over 50 seconds, and the obtained curve was approximated by a straight line, and the agglutination speed was calculated from the slope of the straight line.

Regarding the hemagglutination agent used in the present invention, a preferable one includes a cationic polymer. The cationic polymer may be arranged on the absorbent body or any part of the skin contacting surface side more than the absorbent body, but if the anion-like superabsorbent polymer does not exist in the vicinity of the cationic polymer with the opposite charge , The dissolution of the cationic polymer into the menstrual blood will not be inhibited, and the red blood cells will be easily agglutinated. A sufficient agglutination effect can be obtained before the superabsorbent polymer absorbs the liquid, which is preferable.

Examples of the cationic polymer include cationized cellulose and cationized starch such as hydroxypropyltrimethylammonium chloride starch. In addition, the hemagglutination agent used in the present invention may include a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer, or a quaternary ammonium salt polycondensate as a cationic polymer. In the present invention, the "quaternary ammonium salt" includes a compound having a positive monovalent charge at the position of a nitrogen atom, or a compound having a positive monovalent charge at the position of a nitrogen atom by neutralization, as a specific example thereof. Examples include: salts of quaternary ammonium cations, neutralizing salts of tertiary amines, and tertiary amines having cations in aqueous solution. The "quaternary ammonium part" mentioned below also adopts the same meaning, and it belongs to the part which is positively charged in water. In the present invention, the "copolymer" refers to a polymer obtained by copolymerizing two or more polymerizable monomers, and includes both a binary copolymer and a ternary copolymer or more. In the present invention, the "polycondensate" means that two or more kinds of monomers are contained A polycondensate obtained by polymerizing the condensate.

In the case where the hemagglutinating agent used in the present invention includes a quaternary ammonium salt homopolymer and / or a quaternary ammonium salt copolymer and / or a quaternary ammonium salt polycondensate as a cationic polymer, the hemagglutinating agent may be Any one of a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer, and a quaternary ammonium salt polycondensate may be included, or a combination of any two or more of them may be included. Moreover, a quaternary ammonium salt homopolymer may be used individually by 1 type, and may use 2 or more types together. Similarly, a quaternary ammonium salt copolymer may be used individually by 1 type, and may use 2 or more types together. Furthermore, similarly, a quaternary ammonium salt polycondensate can be used individually by 1 type or in combination of 2 or more type.

Among the various cationic polymers described above, it is particularly preferable to use a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer, or a quaternary ammonium salt polycondensate in terms of the adsorption to red blood cells. In the following description, for convenience, the quaternary ammonium salt homopolymer, quaternary ammonium salt copolymer, and quaternary ammonium salt polycondensate are collectively referred to as "quaternary ammonium salt polymer".

A quaternary ammonium salt homopolymer is obtained by polymerizing a polymerizable monomer having a quaternary ammonium moiety. On the other hand, quaternary ammonium salt copolymers are made by using at least one polymerizable monomer having a quaternary ammonium site and optionally using at least one polymerizable monomer having no quaternary ammonium site. Aggregate and gain. That is, the quaternary ammonium salt copolymer is obtained by using two or more kinds of polymerizable monomers having a quaternary ammonium site, and copolymerizing them, or using one or more kinds of polymerizable monomers having a quaternary ammonium site. And one or more kinds of polymerizable monomers having no quaternary ammonium site, and those obtained by copolymerization of these. The quaternary ammonium salt copolymer may be a random copolymer, an alternating copolymer, a block copolymer, or a graft copolymer. The quaternary ammonium salt polycondensate is obtained by polymerizing these condensates by using a condensate containing one or more types of monomers having a quaternary ammonium moiety. That is, the quaternary ammonium salt polycondensate is obtained by polymerizing two or more types of monomers having a quaternary ammonium site, or using a monomer containing one or more types of quaternary ammonium sites. A condensate with one or more kinds of monomers having no quaternary ammonium site, and obtained by condensation polymerization.

The quaternary ammonium salt polymer is a cationic polymer having a quaternary ammonium site. The quaternary ammonium site can be generated by quaternary ammonium of a tertiary amine using an alkylating agent. Alternatively, the tertiary amine can be dissolved in acid or water and formed by neutralization. Alternatively, it can be generated by using a quaternary ammonium by a nucleophilic reaction including a condensation reaction. Examples of the alkylating agent include a halogenated alkyl group and a dialkyl sulfate such as dimethyl sulfate. Among these alkylating agents, if a dialkyl sulfate is used, it is preferable not to cause the corrosion problem that may occur when using a halogenated alkyl group. Examples of the acid include hydrochloric acid, sulfuric acid, nitric acid, acetic acid, citric acid, phosphoric acid, fluorosulfonic acid, boric acid, chromic acid, lactic acid, oxalic acid, tartaric acid, gluconic acid, formic acid, ascorbic acid, and hyaluronic acid. In particular, if a quaternary ammonium salt polymer obtained by quaternizing a tertiary amine site by an alkylating agent is used, the electric double layer of red blood cells can be reliably neutralized, which is preferable. Regarding the quaternary ammonification by a nucleophilic reaction including a condensation reaction, the ring-opening condensation polymerization reaction of dimethylamine and epichlorohydrin, and the cyclization reaction of dicyandiamide and diethylene triamine can be performed.

From the viewpoint of efficiently forming agglomerates of red blood cells, the molecular weight of the cationic polymer is preferably 2,000 or more, more preferably 10,000 or more, and even more preferably 30,000 or more. When the molecular weight of the cationic polymer is equal to or higher than these values, the cationic polymers between red blood cells are sufficiently entangled with each other, or the cationic polymers between red blood cells are sufficiently crosslinked. The upper limit of the molecular weight is preferably 10 million or less, more preferably 5 million or less, and even more preferably 3 million or less. When the molecular weight of the cationic polymer is below these values, the cationic polymer is well dissolved in menstrual blood. The molecular weight of the cationic polymer is preferably from 2,000 to 10 million, more preferably from 2,000 to 5 million, further preferably from 2,000 to 3 million, and even more preferably from 10,000 to 3 million, especially It is preferably more than 30,000 and less than 3 million. The molecular weight referred to in the present invention is a weight average molecular weight. The molecular weight of the cationic polymer can be controlled by appropriately selecting its polymerization conditions. Yang The molecular weight of the ionic polymer can be measured by the following method.

From the viewpoint of efficiently forming agglomerates of red blood cells, the cationic polymer is preferably water-soluble. The so-called "water-soluble" mentioned here refers to a water solubility of 100 g or more measured by the following method.

The cationic polymer is preferably a structure having a main chain and a plurality of side chains bonded to the main chain. In particular, the quaternary ammonium salt polymer is preferably a structure having a main chain and a plurality of side chains bonded to the main chain. The quaternary ammonium site is preferably present in the side chain. In this case, if the main chain and the side chain are bonded at one point, the flexibility of the side chain is not easily damaged, and the quaternary ammonium site in the side chain can be smoothly adsorbed on the surface of the red blood cells. Of course, in the present invention, the main chain and the side chain of the cationic polymer may be bonded at two or more points. In the present invention, "bonded at one point" means that one carbon atom of the carbon atoms constituting the main chain and one carbon atom at the end of the side chain are bonded by a single bond. The so-called "bonding with two or more points" means that two or more carbon atoms of the carbon atoms constituting the main chain and two or more carbon atoms at the end of the side chain are respectively bonded by a single bond.

When the cationic polymer is a structure having a main chain and a plurality of side chains bonded to the main chain, for example, a quaternary ammonium salt polymer is a polymer having a main chain and a plurality of side chains bonded to the main chain. In the case of a structured one, the carbon number of each side chain is preferably 4 or more, more preferably 5 or more, and even more preferably 6 or more. The upper limit of the carbon number is preferably 10 or less, more preferably 9 or less, and even more preferably 8 or less. For example, the carbon number of the side chain is preferably 4 or more and 10 or less, more preferably 5 or more and 9 or less, and even more preferably 6 or more and 8 or less. The carbon number of the side chain refers to the carbon number of the quaternary ammonium site (cation site) in the side chain. Even if carbon is included in the anion serving as a counter ion, the carbon is not included in the carbon number. Especially if the carbon number of the carbon atoms in the side chain including the carbon atom bonded to the main chain and the carbon atom bonded to the quaternary nitrogen is within the above range, when the quaternary ammonium salt polymer is adsorbed on the surface of the red blood cell The three-dimensional obstruction is low, which is preferable.

When the quaternary ammonium salt polymer is a quaternary ammonium salt homopolymer, examples of the homopolymer include polymers of vinyl-based monomers having a quaternary ammonium site or a tertiary amine site. When a vinyl monomer having a tertiary amine moiety is polymerized, the tertiary ammonium moiety is quaternized with an alkylating agent before the polymerization and / or after the polymerization to form a quaternary ammonium salt. Homopolymer, either before and / or after polymerization, neutralizes the tertiary amine site with an acid to form a tertiary amine neutralization salt, or after polymerization becomes a tertiary amine with a cation in an aqueous solution. Examples of the alkylating agent or the acid are as described above.

The quaternary ammonium salt homopolymer is particularly preferably one having a repeating unit represented by Formula 1 below.

Specific examples of the quaternary ammonium salt homopolymer include polyethyleneimine and the like. In addition, examples of a side chain having a quaternary ammonium site and a main chain bonded at one point include poly (2-methacryloxyethyldimethylamine quaternary salt) and poly (2-methyl Methacryloxyethyl trimethylamine quaternary salt), poly (2-methacryloxyethyl dimethylethylammonium ethyl sulfate), poly (2-propenyloxyethyl Dimethylamine quaternary salt), poly (2-propenyloxyethyltrimethylamine quaternary salt), poly (2-propenyloxyethyldimethylethylammonium ethylsulfate), Poly (3-dimethylaminopropylacrylamide quaternary salt), polydimethylaminoethyl methacrylate, polyallylamine hydrochloride, cationized cellulose, poly Ethyleneimine, polydimethylaminopropylacrylamide, polyfluorene and the like. On the other hand, as examples of a homopolymer having a side chain having a quaternary ammonium site and a main chain bonded at two or more points, polydiallyldimethylammonium chloride, polydiallylamine Hydrochloride.

In the case where the quaternary ammonium salt polymer is a quaternary ammonium salt copolymer, as the copolymer, the following can be used: two or more polymerizable monomers used for the polymerization of the quaternary ammonium salt homopolymer A copolymer obtained by copolymerization. As the quaternary ammonium salt copolymer, it is possible to use one or more polymerizable monomers for polymerization of the above-mentioned quaternary ammonium salt homopolymer, and polymerization of one or more quaternary ammonium salt-free sites. A copolymer obtained by copolymerizing a basic monomer. Further, other polymerizable monomers such as -SO ₂ -and the like may be used together with or instead of vinyl polymerizable monomers. The quaternary ammonium salt copolymer may be a binary copolymer or a ternary copolymer or higher as described above.

From the viewpoint of efficiently forming agglomerates of red blood cells, the quaternary ammonium salt copolymer is particularly preferably one having a repeating unit represented by Formula 1 above and a repeating unit represented by Formula 2 below.

[Chemical 2]

In addition, as the polymerizable monomer having no quaternary ammonium site, a cationic polymerizable monomer, an anionic polymerizable monomer, or a nonionic polymerizable monomer can be used. Among these polymerizable monomers, especially by using a cationic polymerizable monomer or a nonionic polymerizable monomer, the quaternary ammonium salt copolymer does not offset the charge of the quaternary ammonium site, so it can be effectively used. Causes agglutination of red blood cells. Examples of the cationic polymerizable monomer include vinylpyridine, which is a cyclic compound having a nitrogen atom having a cation under a specific condition, and the like, and a nitrogen atom having a cation having a cation under a specific condition on the main chain. The linear compound is a condensation compound of dicyandiamide and diethylene triamine. Examples of the anionic polymerizable monomer include 2-acrylamido-2-methylpropanesulfonic acid, methacrylic acid, acrylic acid, and styrenesulfonic acid, and salts of these compounds. On the other hand, examples of the nonionic polymerizable monomer include vinyl alcohol, acrylamide, dimethylacrylamide, ethylene glycol, propylene glycol, ethylene glycol monomethacrylate, and ethylene glycol. Monoacrylate, hydroxyethyl methacrylate, hydroxyethyl acrylate, methyl methacrylate, methyl acrylate, forma Ethyl acrylate, ethyl acrylate, propyl methacrylate, propyl acrylate, butyl methacrylate, butyl acrylate, and the like. About these cationic polymerizable monomers, anionic polymerizable monomers, or nonionic polymerizable monomers, one kind may be used, or two or more kinds may be used in combination. In addition, two or more kinds of cationic polymerizable monomers may be used in combination, two or more kinds of anionic polymerizable monomers may be used in combination, or two or more kinds of nonionic polymerizable monomers may be used in combination. The quaternary ammonium salt copolymer obtained by copolymerizing a cationic polymerizable monomer, an anionic polymerizable monomer, and / or a nonionic polymerizable monomer as a polymerizable monomer has a molecular weight as described above, It is preferably 10 million or less, particularly preferably 5 million or less, and particularly preferably 3 million or less (the same applies to the quaternary ammonium salt copolymer exemplified below).

As the polymerizable monomer having no quaternary ammonium site, a polymerizable monomer having a functional group capable of forming a hydrogen bond may be used. When such a polymerizable monomer is used for copolymerization, and the quaternary ammonium salt copolymer obtained thereby is used to agglutinate red blood cells, it is easy to form harder agglomerates, and the absorption performance of the superabsorbent polymer is less susceptible to damage. Examples of the functional group capable of forming a hydrogen bond include -OH, -NH ₂ , -CHO, -COOH, -HF, and -SH. Examples of the polymerizable monomer having a functional group capable of forming a hydrogen bond include hydroxyethyl methacrylate, vinyl alcohol, acrylamide, dimethylacrylamide, ethylene glycol, propylene glycol, and ethylene glycol Monomethacrylate, ethylene glycol monoacrylate, hydroxyethyl acrylate, and the like. In particular, hydroxyethyl methacrylate, 2-hydroxyethyl methacrylate, hydroxyethyl acrylate, dimethylacrylamide, etc., which play a strong role in hydrogen bonding, can stabilize the quaternary ammonium salt polymer to red blood cells. The adsorption state is preferred. These polymerizable monomers may be used individually by 1 type, or may be used in combination of 2 or more type.

As the polymerizable monomer having no quaternary ammonium site, a polymerizable monomer having a functional group capable of generating a hydrophobic interaction can also be used. By using such a polymerizable monomer for copolymerization, the same effects as those in the case of using a polymerizable monomer having a functional group capable of forming a hydrogen bond as described above are exhibited. The beneficial effect, that is, the effect of forming harder red blood cell agglomerates easily. Examples of the functional group capable of causing a hydrophobic interaction include alkyl groups such as methyl, ethyl, and butyl, phenyl, alkylnaphthyl, and fluorinated alkyl. Examples of the polymerizable monomer having a functional group capable of generating a hydrophobic interaction include methyl methacrylate, methyl acrylate, ethyl methacrylate, ethyl acrylate, propyl methacrylate, and propyl acrylate. Esters, butyl methacrylate, butyl acrylate, styrene and the like. In particular, hydrophobic interactions play a strong role and do not significantly reduce the solubility of quaternary ammonium salt polymers. Methyl methacrylate, methyl acrylate, butyl methacrylate, butyl acrylate, etc. can achieve quaternary ammonium. The stable adsorption state of the salt polymer to red blood cells is preferred. These polymerizable monomers may be used individually by 1 type, or may be used in combination of 2 or more type.

Regarding the molar ratio of the polymerizable monomer having a quaternary ammonium site to the molar ratio of the polymerizable monomer having no quaternary ammonium site in the quaternary ammonium salt copolymer, it is preferable to use the quaternary ammonium The manner in which the salt copolymer is used to sufficiently agglutinate red blood cells is appropriately adjusted. In particular, the molar content of the polymerizable monomer having a quaternary ammonium moiety in the quaternary ammonium salt copolymer is preferably 10 mol% or more, more preferably 22 mol% or more, and further preferably 32 mol% or more. , And more preferably 38 mol% or more. In addition, it is 100 mol% or less, preferably 80 mol% or less, more preferably 65 mol% or less, and still more preferably 56 mol% or less. Specifically, the molar content of the polymerizable monomer having a quaternary ammonium site is preferably 10 mol% or more and 100 mol% or less, more preferably 22 mol% or more and 80 mol% or less, and more preferably 32 mol% or more and 65 mol% or less, more preferably 38 mol% or more and 56 mol% or less.

In the case where the quaternary ammonium salt polymer is a quaternary ammonium salt polycondensate, as the polycondensate, the following can be used: a condensate containing one or more of the above-mentioned monomers having a quaternary ammonium moiety is used A polycondensate obtained by polymerizing these condensates. Specific examples include dicyandiamide / diethylene triamine condensation polymer, dimethylamine / epichlorohydrin condensation polymer, and the like.

The above-mentioned quaternary ammonium salt homopolymer and quaternary ammonium salt copolymer can be obtained by a homopolymerization method or a copolymerization method of a vinyl-based polymerizable monomer. Examples of the polymerization method include radical polymerization, living radical polymerization, living cationic polymerization, living anionic polymerization, coordination polymerization, ring-opening polymerization, and condensation polymerization. The polymerization conditions are not particularly limited, as long as the conditions that can obtain a quaternary ammonium salt polymer having a target molecular weight, flow potential, and / or IOB value are appropriately selected.

For example, from the viewpoint of more effectively forming agglomerates of red blood cells, the flow potential of the quaternary ammonium salt polymer is preferably 1500 μeq / L or more, more preferably 2000 μeq / L or more, and further preferably 3000 μeq / L or more. More preferably, it is 4000 μeq / L or more. With the flow potential of the quaternary ammonium salt polymer being equal to or higher than this value, the electric double layer of the red blood cells can be fully neutralized. The upper limit of the flow potential is preferably 13,000 μeq / L or less, more preferably 8000 μeq / L or less, and even more preferably 6000 μeq / L or less. Since the flow potential of the quaternary ammonium salt polymer is equal to or less than this value, the quaternary ammonium salt polymer adsorbed on the red blood cells can be effectively prevented from generating an electric repulsive force with each other.

The flow potential of the quaternary ammonium salt polymer can be determined, for example, by copolymerizing the molecular weight of the cationic monomer itself constituting the copolymer, the copolymerization of the cationic monomer constituting the copolymer, the anionic monomer, or the nonionic monomer. Ratio to control. The flow potential of the quaternary ammonium salt polymer can be measured using a flow potentiometer (PCD04) manufactured by Spectris Corporation. Specific measurement conditions are as follows. First, with respect to commercially available physiological products, a dryer or the like is used to disable the hot melt of each component, and the components are decomposed into components such as a front sheet, an absorber, and a back sheet. The decomposed components are subjected to a multi-stage solvent extraction method from a non-polar solvent to a polar solvent, and the treating agent used in each component is separated to obtain a solution containing a single composition. The obtained solution was dried and solidified, and ¹ H-NMR (nuclear magnetic resonance method), IR (infrared spectroscopy), LC (liquid chromatography), GC (gas chromatography), MS (mass spectrometry), GPC (Gel permeation chromatography), fluorescent X-ray, and the like are combined to identify the structure of the treatment agent. 0.001 g of the treatment agent (quaternary ammonium salt polymer) to be measured was dissolved in 10 g of physiological saline solution to obtain a measurement sample, and the measurement sample was titrated with a 0.001 N aqueous solution of sodium polyvinylsulfonate (a negative charge in the measurement sample). In this case, a polydiallyldimethylammonium chloride aqueous solution of 0.001 N) was used to measure the titer amount X mL required until the potential difference between the electrodes disappeared. Thereafter, the flow potential of the quaternary ammonium salt polymer was calculated according to the following formula.

Flow potential = (X + 0.190 ^※ ) × 1000

(※ Titration volume of solvent for physiological saline)

In addition, in order to smoothly adsorb the quaternary ammonium salt polymer on the surface of red blood cells, it is advantageous that the quaternary ammonium salt polymer easily interacts with the sialic acid. Based on this viewpoint, the present inventors conducted research, and as a result, determined the value of the inorganic value / organic value (hereinafter referred to as "IOB (Inorganic Organic Balance, Inorganic / Organic)" which can be used as the ratio of the inorganic value to the organic value. The "balance" value ") is used as a scale to evaluate the degree of interaction between the sialic acid bond and the cationic polymer.

Generally speaking, the properties of a substance are dominated by various intermolecular forces between molecules. The intermolecular forces mainly include Van Der Waals force based on molecular mass and electrical affinity based on molecular polarity. . If it is possible to grasp each of Van der Waals and electrical affinities that have a greater impact on changes in the properties of matter, then based on their combination, even if it is an unknown substance or a mixture of these, the properties can be predicted. This idea is known to the public as the "Organic Concept Map Theory". Organic conceptual map theories such as "Organic Analysis" (Kaniya Shoten, 1930) by Fujita Mu (author), Qualitative Organic Analysis: Systematic Pure Matter by Fujimura (Author, Kyoritsu Publishing, 1953), Fujita Mu (author) "Adapted Chemistry Experiment-Organic Chemistry" (Kawasuke Den, 1971), Fujita Mu / Akazu Masaru (author) "Systematic Organic Qualitative Analysis (Mixture)" (Kazama Den, 1974) , And "The Basics and Applications of the New Organic Concept Map" (Sankyo Publishing, 2008), etc. According to the organic concept map theory, regarding the physical and chemical physical properties of matter, the degree of physical properties mainly based on van der Waals is called "organicity". The degree of physical properties mainly based on electrical affinity is referred to as "inorganicity", and the physical properties of a substance are determined in the form of a combination of "organicity" and "inorganicity." In addition, one carbon (C) is defined as organic, and the inorganic and organic values of various polar groups are defined as described in Table 1 below. The sum of the inorganic values and the organic values are obtained. The sum of the two is defined as the IOB value. In the present invention, the IOB value of the sialic acid bonded substance is determined based on the organic value and the inorganic value, and the IOB value of the cationic polymer is determined based on the value.

In detail, it is judged that it is advantageous to use, as a cationic polymer, an IOB value equal to or similar to the IOB value of the sialic acid bond. Sialic acid bond Examples of the compound in a sufficient form include a compound in which sialic acid is bonded to a terminal of a glycolipid such as galactose lipid. The IOB value of sialic acid was 4.25 as sialic acid monomer and 3.89 as sialic acid bond. The so-called sialic acid-linked substance is a glycoside in which a sugar chain and a sialic acid are bonded. Compared with a sialic acid monomer, the ratio of the sialic acid-bonded substance has a higher organic value and a lower IOB value.

Therefore, the IOB value of the quaternary ammonium salt polymer is preferably 0.6 or more, more preferably 1.8 or more, more preferably 2.1 or more, and even more preferably 2.2 or more. The IOB value of the cationic polymer is preferably 4.6 or less, more preferably 3.6 or less, and even more preferably 3 or less. The IOB value is more preferably 1.8 or more and 3.6 or less, more preferably 2.1 or more and 3.6 or less, and even more preferably 2.2 or more and 3 or less.

In the case where the quaternary ammonium salt polymer is a copolymer, based on the molar ratio of the monomers used for copolymerization, the IOB value is calculated according to the following procedure. That is, the copolymer is obtained from monomer A and monomer B, and the organic value of monomer A is OR _A and the inorganic value is IN _A , and the organic value of monomer B is OR _B and inorganic value. When it is IN _B and the molar ratio of monomer A / monomer B is M _A / M _B , the IOB value of the copolymer is calculated according to the following formula.

In addition, the hemagglutination agent used in the present invention may include one or more third components in addition to polycations (cationic polymers), such as solvents, plasticizers, fragrances, antibacterial and deodorants, and skin care. The form of a composition (hemagglutination agent composition) of other components such as an agent. As the solvent, water-soluble organic solvents such as water and saturated aliphatic monohydric alcohols having 1 to 4 carbons, or mixed solvents of the water-soluble organic solvents and water, and the like can be used. As the plasticizer, glycerin, polyethylene glycol, and propylene diamine can be used. Alcohol, ethylene glycol, 1,3-butanediol, and the like. As the fragrance, the fragrance described in Japanese Patent Laid-Open No. 2007-244764, which has a fragrance similar to that of green herbs, extracts of plants, extracts of citrus, and the like can be used. As the antibacterial and deodorant, it is possible to use a mineral such as calcinite, which contains a metal having antibacterial properties, as described in Japanese Patent Laid-Open No. 2004-244789, and a benzene-containing material described in Japanese Patent Laid-Open No. 2007-097953. A porous polymer formed by polymerizing a polymerizable monomer based on a base, a quaternary ammonium salt described in Japanese Patent Laid-Open No. 2006-191966, activated carbon, clay minerals, and the like. As the skin care agent, plant extracts, collagen, natural moisturizing ingredients, moisturizing agents, keratin softeners, anti-inflammatory agents, etc. described in Japanese Patent Laid-Open No. 2004-255164 can be used.

The proportion of the cationic polymer in the blood cell agglutinant composition is preferably 20% by mass or more, more preferably 40% by mass or more, and even more preferably 50% by mass or more. The content is preferably 99% by mass or less, more preferably 80% by mass or less, and still more preferably 60% by mass or less. By setting the ratio of the cationic polymer in the above-mentioned hemagglutinating agent composition to be within this range, an effective amount of the cationic polymer can be imparted to a physiological product.

From the viewpoint that the blood cell agglutinating agent contained in the physiological article functions reliably by dissolving into the blood to form a large agglomerate, its content is preferably 0.01 g / m ² or more, and more preferably 0.5 g. / m ² or more. Further, the blood cell aggregating agent contained in the sanitary products on the viewpoint of the liquid-permeable non-destructive, the content thereof is preferably 20g / m ² or less, more preferably 10g / m ² or less. Specifically, the content of the hemagglutinating agent contained in the physiological article is preferably 0.01 g / m ² or more and 20 g / m ² or less, and more preferably 0.5 g / m ² or more and 10 g / m ² or less.

(Liquid film cracking agent)

The so-called liquid film cleaving agent refers to an agent that causes a liquid, such as menstrual blood, highly viscous excretion fluid to contact a non-woven fabric, to crack a liquid film formed on or between fibers of the non-woven fabric, or to inhibit the formation of a liquid film. It has the effect of cracking the formed liquid film and the effect of inhibiting the formation of the liquid film. The former can be described as the main role, and the latter can be described as the subordinate role. The cracking of the liquid film is achieved by pushing a part of the liquid film layer away from the liquid film cracking agent to make it unstable. By the action of the liquid film cleaving agent, the liquid does not stay in the narrow area between the fibers of the non-woven fabric and easily passes through. That is, it becomes a nonwoven fabric excellent in liquid permeability. Thereby, even if the fibers constituting the non-woven fabric are thinned and the distance between the fibers is narrowed, the soft skin feeling and the residual liquid are suppressed at the same time. In addition, in the present invention, by using a blood agglutinating agent, the absorption performance originally possessed by the superabsorbent polymer can be stably exerted to effectively suppress liquid backflow. On the other hand, the surface of the physiological article (skin contact surface) after use ) Color, there is a tendency that the whiteness of the surface is greatly reduced and the redness of blood origin is enhanced when it is not used. The reduction of the surface whiteness caused by the aggregating agent can simultaneously reduce the amount of liquid return and increase the surface whiteness after use.

As for the liquid film cracking effect, as long as a liquid film cracking agent is disposed at a place where a liquid film may exist, the liquid film cracking agent is not limited to being produced only between non-woven fibers. For example, in an absorbent body with fluff pulp or a superabsorbent polymer, it is formed between the fibers of the fluff pulp, or between the particles of the superabsorbent polymer, and between the fluff pulp and the superabsorbent polymer particles. Liquid film can also produce liquid film cracking effect.

In the present invention, the constituent material of the so-called physiological article contains or contains a liquid film cleaving agent, which mainly refers to a state of being attached to the surface of the material. Among them, for example, when the fiber contains a liquid film cleaving agent, as long as the liquid film cleaving agent remains on the surface of the fiber, the liquid film cleaving agent may be contained in the fiber or may exist in the fiber by internal addition.

In order that the liquid film cleaving agent of the present invention has the following liquid film cleaving effect in a physiological article, the liquid film cleaving agent must exist in a liquid state when it contacts a body fluid. In this respect, the melting point of the liquid film cleaving agent of the present invention is preferably 40 ° C or lower, more preferably 35 ° C or lower. Further, the liquid film of the present invention opens The melting point of the cracking agent is preferably -220 ° C or higher, and more preferably -180 ° C or higher.

(Properties to make liquid film disappear)

The liquid film cleaving agent used in the present invention has the property of causing the liquid film to disappear, and by virtue of this property, the liquid film cleaving agent can exhibit the liquid film disappearing effect when the liquid film cleaving agent is applied to a test liquid mainly composed of a plasma component. . The liquid film disappearing effect mentioned here includes an effect of suppressing the formation of a liquid film of a structure formed on a plurality of liquid films formed by a test solution with air inside, and a structure of the formed liquid disappearing. Effects These two effects, the agent exhibiting at least one effect can be said to have the property of exhibiting the effect of disappearing the liquid film.

The above test solution is a liquid component obtained from defibrillated horse blood (manufactured by Nippon Bio-Test Laboratories Co., Ltd.). Specifically, if 100 mL of defibrillated horse blood is allowed to stand at a temperature of 22 ° C. and a humidity of 65% for 1 hour, the defiber horse blood is separated into an upper layer and a lower layer, and the upper layer is the above-mentioned test solution. The upper layer contains mainly plasma components and the lower layer contains mainly blood cells. In order to remove only the upper layer from the defibrillated horse blood separated into the upper layer and the lower layer, a pipette (manufactured by NIPPON MICRO Co., Ltd.) can be used, for example.

Whether or not a certain agent has the above-mentioned "dissolving property of the liquid film" is based on the structure when the structure is prone to produce a structure in which air is contained in the liquid film formed by the test solution to which the agent is applied. That is, the amount of the liquid film is judged. That is, the temperature of the test solution was adjusted to 25 ° C., and then 10 g was put into a spiral tube (manufactured by Maruemu Co., Ltd., No. 5, cylinder diameter 27 mm, total length 55 mm) to obtain a standard sample. In addition, 0.01 g of the agent to be measured in advance adjusted to 25 ° C. was added to the same sample as the standard sample, and the obtained sample was used as the measurement sample. The standard sample and the measurement sample were reciprocated twice in the upward and downward directions of the spiral tube, and after being strongly vibrated, they were quickly placed on a horizontal surface. By the vibration of the sample, a liquid layer (lower layer) without the above structure is formed inside the spiral tube after the vibration, and a plurality of liquid layers including the liquid layer formed on the liquid layer are formed. The structure layer (upper layer) of the structure. After the lapse of 10 seconds immediately after the vibration, the height of the structural layer (the height from the liquid surface of the liquid layer to the upper surface of the structural layer) of the two samples was measured. Furthermore, when the height of the structure layer of the measurement sample is 90% or less with respect to the height of the structure layer of the standard sample, it is judged that the agent to be measured has a liquid film cracking effect.

The liquid film cracking agent used in the present invention is a single compound that meets the above-mentioned properties or a mixture of a plurality of single compounds that meets the above-mentioned properties, or satisfies the above-mentioned properties by combining a plurality of compounds (which can achieve liquid Film cracking) agent. That is, the liquid film cracking agent is limited to an agent having a liquid film cracking effect based on the above definition. Therefore, when the compound used in a physiological article contains a third component that does not meet the above definition, it is different from a liquid film cracking agent. In addition, the "single compound" in this specification is a concept including the compound which has the same compositional formula, but has a different molecular weight due to the different number of repeating units.

As the liquid film cracking agent, those described in International Publication No. 2016/098796 can be arbitrarily used.

Hereinafter, preferred embodiments of the liquid film cleaving agent of the present invention will be described. As the liquid film cracking agent of the present invention, there are two types of the first embodiment and the second embodiment which are preferred.

The liquid film cracking agent of the first embodiment is compound C1. The compound C1 is a compound having an expansion coefficient of a liquid having a surface tension of 50 mN / m of 15 mN / m or more, and a water solubility of 0 g or more and 0.025 g or less.

The so-called "expansion coefficient for a liquid having a surface tension of 50 mN / m" possessed by the liquid film cleaving agent of the first embodiment refers to the expansion coefficient when a liquid such as menstrual blood is excreted as described above. The so-called "expansion coefficient" is a value calculated based on the following formula (1) based on a measurement value obtained by the following measurement method in an environmental region of a temperature of 25 ° C and a relative humidity (RH) of 65%. Furthermore, the "liquid film" in γ _w and γ _wo in formula (1) means a liquid phase of "a liquid having a surface tension of 50 mN / m", and includes a liquid in a state where a film is formed between fibers or on the fiber surface, Both liquids in a state before forming a film are also referred to as liquids for short. In addition, "surface tension" in γ _w and γ _o in the following formula (1) means the interfacial tension at the interface between the liquid film and the liquid film cleaving agent and the gas phase, which is different from the liquid film cleaving agent between the liquid phase and Interfacial tension of the liquid film. This difference is the same as in other descriptions of this specification.

S = γ _w -γ _o -γ _wo ‧‧‧‧‧ (1)

γ _w : surface tension of liquid film (liquid)

γ _o : surface tension of liquid film cracking agent

γ _wo ： Interfacial tension between liquid film cracking agent and liquid film

According to the above formula (1), it can be known that the expansion coefficient (S) of the liquid film cleaving agent becomes larger as the surface tension (γ _o ) of the liquid film cleaving agent becomes smaller, and the interfacial tension between the liquid film cleaving agent and the liquid film (γ _wo ) Gets smaller and bigger. When the expansion coefficient is 15 mN / m or more, the liquid film cleaving agent of the first embodiment has high mobility, that is, diffusivity, on the surface of the liquid film formed in the narrow region between the fibers. From this viewpoint, the expansion coefficient of the liquid film cracking agent of the first embodiment is more preferably 20 mN / m or more, more preferably 25 mN / m or more, and even more preferably 30 mN / m or more. On the other hand, the upper limit is not particularly limited, but according to the above formula (1), for example, when the liquid having a surface tension of 50 mN / m is used, the upper limit value is 50 mN / m, and when the liquid having a surface tension of 60 mN / m is used. In the case of a liquid, the upper limit is 60 mN / m, and in the case of using a liquid with a surface tension of 70 mN / m, the upper limit is 70 mN / m. Thus, the surface tension of the liquid forming the liquid film becomes the upper limit. Therefore, in the present invention, from the viewpoint of using a liquid having a surface tension of 50 mN / m, the expansion coefficient of the liquid film cleaving agent of the first embodiment is 50 mN / m or less.

The liquid film cleaving agent of the first embodiment has a water solubility of 0 g to 0.025 g, and is difficult to dissolve in an aqueous liquid to form an interface with a liquid film, thereby making the above-mentioned diffusibility more effective. From the same viewpoint, the water solubility of the liquid film cleaving agent of the first embodiment is preferably 0.025 g or less, more preferably 0.0017 g or less, and still more preferably 0.0001 g or less. In addition, the smaller the water solubility, the better, and it is 0 g or more. From the viewpoint of diffusibility to a liquid film, it is actually set to 1.0 × 10 ^-9 g or more. Moreover, it is thought that the said water solubility is also applicable to menstrual blood etc. which have water as a main component. The water solubility of the liquid film cleaving agent can be measured by the following method.

The surface tension (γ _w ) of the liquid film (a liquid having a surface tension of 50 mN / m), the surface tension of the liquid film cracking agent (γ _o ), and the interfacial tension of the liquid film cracking agent and the liquid film (γ _wo ) are determined by It measured by the following method.

(Method for measuring surface tension (γ _w ) of liquid film (liquid))

It can be measured by a plate method (Wilhelmy method) using a platinum plate in an environmental area with a temperature of 25 ° C and a relative humidity (RH) of 65%. As the measuring device at this time, an automatic surface tension meter "CBVP-Z" (trade name, manufactured by Kyowa Interface Science Co., Ltd.) can be used. The platinum plate uses 99.9% purity and size: 25mm in length / 10mm in width.

In addition, the "liquid with a surface tension of 50 mN / m" is a polyoxyethylene sorbitan monolaurate (made by Kao Corporation, RHEODOL SUPER TW-L120) and a solution adjusted to 50 ± 1 mN / m.

(Method for measuring surface tension (γ _o ) of liquid film cracking agent)

Similar to the measurement of the surface tension (γ _w ) of the liquid film, the measurement can be performed by the flat plate method in an environmental region having a temperature of 25 ° C. and a relative humidity (RH) of 65% using the same device. At the time of the measurement, as described above, when the obtained liquid film cracking agent is solid, the liquid film cracking agent is heated to its melting point + 5 ° C to make the phase transfer to a liquid, and the temperature conditions are kept unchanged. The measurement was performed.

(Measurement method of interfacial tension (γ _wo ) between liquid film cracking agent and liquid film)

It can be measured by the hanging drop method in an environmental area with a temperature of 25 ° C and a relative humidity (RH) of 65%. As the measuring device at this time, an automatic interface viscoelasticity measuring device can be used. (The product name is THE TRACKER manufactured by TECLIS-ITCONCEPT, or the product name is DSA25S manufactured by KRUSS.) With regard to the hanging drop method, at the same time as the formation of droplets, the adsorption of non-ionic interfacial active substances contained in a liquid having a surface tension of 50 mN / m begins, and the interface tension gradually decreases with time. Therefore, the interfacial tension at which droplets are formed (at 0 seconds) is read. In this measurement, as described above, when the obtained liquid film cleaving agent is solid, the liquid film cleaving agent is heated to its melting point + 5 ° C to transfer the phase to a liquid, and the temperature conditions are maintained. The measurement was performed unchanged.

In addition, when measuring the interfacial tension, there are cases in which the density difference between the liquid film cracking agent and the liquid with a surface tension of 50mN / m is very small, or the viscosity is significantly higher, and the interfacial tension value is the measurement limit of the hanging drop method. In the following cases, it is difficult to measure the interfacial tension by the hanging drop method. In this case, the measurement can be performed by the spin-drop method in an environmental area where the temperature is 25 ° C. and the relative humidity (RH) is 65%. As a measuring device at this time, a spin drop interfacial tensiometer (trade name: SITE100, manufactured by KURUSS) can be used. For this measurement, the interfacial tension when the shape of the droplet is stabilized is also read. When the obtained liquid film cleaving agent is solid, the liquid film cleaving agent is heated to its melting point + 5 ° C to make it phase. It was transferred to a liquid, and the measurement was performed while maintaining the temperature conditions.

Furthermore, when both types of measuring devices can measure the interfacial tension, a smaller interfacial tension value is used as the measurement result.

The liquid film cracking agent of the first embodiment has the above-mentioned expansion coefficient and water solubility, can diffuse on the surface of the liquid film without dissolution, and pushes the liquid film layer away from the center of the liquid film. As a result, the liquid film is destabilized and cracked.

Here, the liquid film cleaving effect of the liquid film cleaving agent in the absorbent body of the first embodiment will be specifically described with reference to FIGS. 3 and 4 by taking a case where a liquid film cleaving agent is disposed on a nonwoven fabric.

FIG. 3 shows a state in which a liquid film 8 is formed in the gap between the fibers 7 constituting the nonwoven fabric, and FIG. 4 shows a process in which the liquid film 8 is cracked by the action of the liquid film cleaving agent 9. As shown in FIG. 3, in a narrow area between fibers, excretory fluid with high viscosity such as menstrual blood tends to form a liquid film 8. In contrast, the liquid film cleaving agent 9 causes the liquid film 8 to become unstable and rupture as described below, suppresses the formation of the liquid film 8, and promotes the discharge of liquid from the nonwoven fabric. First, as shown in FIGS. 4 (A1) and (B1), the non-woven fiber 7 has a liquid film cleaving agent 9 attached to the surface of the fiber 7 from the fiber 7 to the liquid film 8 and further maintains the liquid film 8 The state of the interface of the film 8 moves on the surface of the liquid film 8. Then, as shown in FIGS. 4 (A2) and (B2), the liquid film cracking agent 9 pushes a part of the liquid film 8 away and penetrates into the thickness direction of the liquid film 8 as shown in FIGS. 4 (A3) and (B3). As shown, the liquid film 8 is gradually changed to an uneven and thin film. As a result, as shown in FIGS. 4 (A4) and (B4), the liquid film 8 cracked like a crack, and cracked. Liquids such as menstrual blood formed as the liquid film 8 in this way become droplets and easily pass between the fibers of the non-woven fabric, so the residual liquid is reduced.

The cracking effect of the liquid film cracking agent on the liquid film is not limited to the case of the liquid film between the intersecting fibers as shown in FIG. 3, and the liquid film cracking agent also acts similarly to the liquid film adhered to the surface of the fibers. That is, the liquid film cracking agent can move on the liquid film adhered to the surface of the fiber to push a part of the liquid film away, thereby cracking the liquid film. In this case, for the liquid film adhered to the fiber surface, the liquid film cracking agent can crack the liquid film by its hydrophobic effect even if the liquid film cracking agent itself does not move to the liquid film on the fiber surface. , Inhibit the formation of liquid film.

In the first embodiment, the liquid film cracking agent is more preferably such that the interfacial tension to a liquid having a surface tension of 50 mN / m is 20 mN / m or less. That is, the "interfacial tension between the liquid film cleaving agent and the liquid film (γ _wo )" that determines one of the values of the expansion coefficient (S) in the formula (1) is preferably 20 mN / m or less. By suppressing the "interfacial tension (γ _wo ) of the liquid film cracking agent and the liquid film" to be low, the expansion coefficient of the liquid film cracking agent is increased, and the liquid film cracking agent is easy to move from the fiber surface to the vicinity of the liquid film center. Become clearer. From this viewpoint, the "interfacial tension of a liquid film cracking agent with a surface tension of 50 mN / m" is more preferably 17 mN / m or less, still more preferably 13 mN / m or less, and still more preferably 10 mN / m or less. Particularly preferred is 9 mN / m or less, particularly preferred is 1 mN / m or less. On the other hand, the lower limit is not particularly limited, and from the viewpoint of insolubility in the liquid film, it may be greater than 0 mN / m. Furthermore, when the interfacial tension is 0 mN / m, that is, when the liquid film cleaving agent is dissolved in the liquid film, an interface cannot be formed between the liquid film and the liquid film cleaving agent. Therefore, the above formula (1) does not hold, and the agent does not occur. expansion.

It is also known from the above formula (1) that the value of the expansion coefficient changes according to the surface tension of the liquid to be targeted. For example, when the surface tension of the target liquid is 72 mN / m, the surface tension of the liquid film cleaving agent is 21 mN / m, and the interfacial tension of these is 0.2 mN / m, the expansion coefficient becomes 50.8 mN / m.

When the surface tension of the target liquid is 30 mN / m, the surface tension of the liquid film cleaving agent is 21 mN / m, and the interfacial tension of these is 0.2 mN / m, the expansion coefficient becomes 8.8 mN / m.

In any case, the larger the expansion coefficient, the greater the liquid film cracking effect.

In this specification, the value when the surface tension is 50mN / m is defined. However, even if the surface tension is different, the relationship between the values of the expansion coefficients of the substances does not change. Therefore, even if the surface tension of the body fluid is assumed to vary by day Similarly, when the physical condition changes, the agent with a larger expansion coefficient exhibits an excellent liquid film cracking effect.

In the first embodiment, the surface tension of the liquid film cracking agent is preferably 32 mN / m or less, more preferably 30 mN / m or less, even more preferably 25 mN / m or less, and even more preferably 22 mN / m or less. The lower the surface tension, the better. The lower limit is not particularly limited. From the viewpoint of durability of the liquid film cleaving agent, it is actually 1 mN / m or more.

Next, a liquid film cleaving agent according to the second embodiment will be described.

The liquid film cleaving agent of the second embodiment is compound C2. Compound C2 has a coefficient of expansion for a liquid with a surface tension of 50 mN / m greater than 0 mN / m, that is, a positive value, a water solubility of 0 g to 0.025 g, and an interface tension of 20 mN for a liquid with a surface tension of 50 mN / m. / m or less. Setting the "Interfacial tension to a liquid having a surface tension of 50 mN / m" to 20 mN / m or less as described above means that the diffusivity of the liquid film cleaving agent on the liquid film is improved. Therefore, even when the expansion coefficient for a liquid with a surface tension of 50 mN / m is less than 15 mN / m, the diffusion coefficient is relatively high, so a large number of liquid film cracking agents The fiber surface is dispersed into the liquid film, and the liquid film is pushed away at a plurality of positions, whereby the same liquid film cracking effect as in the case of the first embodiment can be exhibited.

Furthermore, the so-called "expansion coefficient for a liquid having a surface tension of 50 mN / m", "water solubility", and "interfacial tension for a liquid having a surface tension of 50 mN / m" regarding the liquid film cracking agent are the same as those in the first embodiment. The special definitions are the same, and the measurement methods are the same.

In the second embodiment, from the viewpoint of making the above-mentioned effect of the liquid film cracking agent more effective, the "Interfacial tension to a liquid having a surface tension of 50 mN / m" is preferably 17 mN / m or less, and more preferably 13 mN / m. m or less, more preferably 10 mN / m or less, still more preferably 9 mN / m or less, and even more preferably 1 mN / m or less. The lower limit value is not particularly limited in the same manner as in the first embodiment. From the viewpoint of being insoluble in a liquid film (a liquid having a surface tension of 50 mN / m), it is actually set to be greater than 0 mN / m.

In addition, regarding the "expansion coefficient for a liquid having a surface tension of 50 mN / m", from the viewpoint of making the above-mentioned effect of the liquid film cracking agent more effective, it is preferably 9 mN / m or more, more preferably 10 mN / m or more, It is more preferably 15 mN / m or more. The upper limit is not particularly limited, and from the viewpoint that the surface tension of the liquid forming the liquid film becomes the upper limit according to the above formula (1), it is substantially 50 mN / m or less.

Further, the preferable ranges of the surface tension and water solubility of the liquid film cleaving agent are the same as those of the first embodiment.

Regarding the liquid film cleaving agent of the first embodiment and the second embodiment, when the liquid film cleaving agent is contained in a nonwoven fabric containing synthetic resin fibers, a paper containing cellulose fibers, or an absorbent core material, it is more preferred Contains phosphate anionic surfactant. Thereby, the hydrophilicity of the fiber surface is improved, and the wettability is improved, so that the contact area between the liquid film and the liquid film cleaving agent becomes larger, and the blood contains a surface-active substance having a phosphate group derived from a living body, and therefore, a combination of phosphoric acid Because of the compatibility of the active agent, the affinity with the phospholipids contained in the blood is also better. Therefore, the liquid film cleaving agent is easy to move to the liquid film, further promoting the liquid film cracking. The content ratio of the liquid film cracking agent and the phosphate ester anionic surfactant is based on the mass ratio, and is set to the former: the latter, preferably 1: 1 to 19: 1, more preferably 2: 1 to 15: 1, and more It is preferably 3: 1 to 10: 1. The above-mentioned content ratio is set to the former: the latter in terms of mass ratio, particularly preferably 5: 1 to 19: 1, more preferably 8: 1 to 16: 1, and even more preferably 11: 1 to 13: 1.

The phosphate ester type anionic surfactant can be used without particular limitation. Specific examples thereof include alkyl ether phosphates, dialkyl phosphates, and alkyl phosphates. Among these, alkyl phosphate is preferred from the viewpoint of improving the affinity of the liquid film cleaving agent containing the liquid film and the liquid film and imparting the processability of the nonwoven fabric.

Next, specific examples of the liquid film cleaving agent of the first embodiment and the second embodiment will be described. These have the properties of being insoluble in water or poorly soluble in water because of being within the above-mentioned specific numerical range, and exhibiting a liquid film cracking effect. In contrast, the surfactant used previously as a fiber treatment agent is equivalent to being dissolved in water and used in actual use, and is basically water-soluble, and is not a liquid film cracking agent of the present invention.

As the liquid film cracking agent of the first embodiment and the second embodiment, a weight average molecule is preferred Compounds in an amount of 500 or more. The weight average molecular weight has a great influence on the viscosity of the liquid film cracking agent. By maintaining a high viscosity, it is difficult for the liquid to flow when passing through the constituent material, and the continuity of the cracking effect of the liquid film can be maintained. From the viewpoint of becoming a viscosity that sufficiently maintains the cracking effect of the liquid film, the weight average molecular weight of the liquid film cracking agent is more preferably 1,000 or more, further preferably 1,500 or more, and even more preferably 2,000 or more. On the other hand, from the viewpoint of making the liquid film cleaving agent self-contained with the liquid film cleaving agent, the constituent material moves to the liquid film, that is, the viscosity is maintained, preferably 50,000 or less, more preferably 20,000. Hereinafter, it is more preferably 10,000 or less.

In addition, as the liquid film cleaving agent of the first embodiment, a compound having at least one structure selected from the group consisting of structures X, X-Y, and Y-X-Y is preferable. The structures X and Y mentioned here are specifically the following structures. In the following structures, "C" represents a carbon atom, and "<", ">", and "-" each represent a bond.

Structure X means> C (A)-, -C (A) _2- , -C (A) (B)-,> C (A) -C (R ¹ ) <,> C (R ¹ )-,- C (R ¹ ) (R ² )-, -C (R ¹ ) ₂ -,> C <, and -Si (R ¹ ) ₂ O-, -Si (R ¹ ) (R ² ) O- A siloxane chain with a basic structure that repeatedly appears or a combination of two or more structures, or a mixed chain thereof. The structure X has a terminal selected from a hydrogen atom, or -C (A) ₃ , -C (A) ₂ B, -C (A) (B) ₂ , -C (A) ₂ -C (R ¹ ) ₃ , -C (R ¹ ) ₂ A, -C (R ¹ ) ₃ , or -OSi (R ¹ ) ₃ , -OSi (R ¹ ) ₂ (R ² ), -Si (R ¹ ) ₃ , -Si ( At least one kind of group in the group consisting of R ¹ ) ₂ (R ² ).

The aforementioned R ¹ or R ² each independently represent a hydrogen atom, an alkyl group (preferably a carbon number of 1 to 20. For example, a methyl group, an ethyl group, or a propyl group), an alkoxy group (preferably a carbon number of 1 to 2) 20. For example, various substituents such as a methoxy group and an ethoxy group), an aryl group (preferably a carbon number of 6 to 20. For example, a phenyl group are preferred), and a halogen atom (for example, a fluorine atom is preferred). A and B each independently represent a substituent including an oxygen atom or a nitrogen atom such as a hydroxy group or a carboxylic acid group, an amine group, an amidino group, an imino group, or a phenol group. When there are a plurality of R ¹ , R ² , A, and B in the structure X, these may be the same as or different from each other. In addition, the continuous bond between C (carbon atom) or Si is usually a single bond, but may also include a double bond or triple bond, and the bond between C or Si may also include an ether group (-O-), amidino group ( -CONR ^A- : R ^A is a hydrogen atom or a monovalent group), an ester group (-COO-), a carbonyl group (-CO-), a carbonate group (-OCOO-), and other linking groups. The number of C and Si bonds with other C or Si is 1-4, and there may also be long-chain polysiloxane chains (siloxane chains) or mixed chains with branched or radial structures. .

The structure Y represents a hydrophilic group containing an atom selected from the group consisting of a hydrogen atom, a carbon atom, an oxygen atom, a nitrogen atom, a phosphorus atom, and a sulfur atom and having hydrophilicity. For example, it is a hydroxyl group, a carboxylic acid group, an amine group, an amido group, an imine group, a phenol group, and a polyoxyalkylene group (the carbon number of the oxyalkylene group is preferably 1 to 4. For example, polyoxyethylene ( POE) group, polyoxypropylene (POP) group), sulfonic acid group, sulfuric acid group, phosphate group, sulfobetaine, carbonyl betaine, phosphate betaine (these betabases refer to each betaine A betaine residue obtained by removing one hydrogen atom from a compound), a quaternary ammonium group, or the like, or a hydrophilic group containing a combination thereof. In addition to these, the following groups and functional groups listed for M ¹ may be mentioned. Furthermore, when Y is plural, such as the structure YXY, the plural Ys may be the same as or different from each other.

In the structures X-Y and Y-X-Y, Y is bonded to X or a terminal group of X. In the case where Y is bonded to a radical at the end of X, the radical at the end of X is bonded to Y, for example, by removing hydrogen atoms whose number is equal to the number of bonds to Y.

In this structure, the hydrophilic groups Y, A, and B can be selected from the specified bases to satisfy the aforementioned expansion coefficient, water solubility, and interfacial tension. This shows the target liquid film cracking effect.

The liquid film cleaving agent of the first embodiment is preferably a compound whose structure X is a siloxane structure. Furthermore, in the liquid film cleaving agent of the first embodiment, it is preferable to include an arbitrary combination of the structures represented by the following formulas (1) to (11), which are specific examples of the structures X, XY, and YXY. A compound of the siloxane chain. Furthermore, from the viewpoint of liquid film cracking effect, the compound preferably has There is a weight average molecular weight in the above range.

In the formulae (1) to (11), M ¹ , L ¹ , R ^21, and R ²² represent the following monovalent or polyvalent (divalent or higher) bases. R ²³ and R ²⁴ represent the following monovalent or polyvalent (divalent or more) bases or single bonds.

M ¹ represents a group having a polyoxyethylene group, a polyoxypropylene group, a polyoxybutenyl group, or a combination of these polyoxyalkylene groups, or an erythritol group, a xylitol group, and a sorbitol group , Glyceryl or ethylene glycol-containing hydrophilic groups having a plurality of hydroxyl groups (hydrophilic groups obtained by removing one hydrogen atom from the above compounds having a plurality of hydroxyl groups such as erythritol), hydroxyl groups, carboxylic acid groups, mercapto groups, Alkoxy (preferably carbon number 1-20. For example, methoxy is preferred), amine, amido, imine, phenol, sulfonic, quaternary ammonium, sulfobetaine , Hydroxysulfobetaine, phosphate betaine, imidazolium betaine, carbonyl betaine, epoxy group, carbinol group, (meth) acryl group, or a combination of these functions base. When M ¹ is a polyvalent group, M ¹ represents a group obtained by removing one or more hydrogen atoms from each of the aforementioned groups or functional groups.

L ¹ represents an ether group, an amine group (the amine group that can be adopted as L ¹ is represented by> NR ^C (R ^C is a hydrogen atom or a monovalent group)), an amino group, an ester group, a carbonyl group, or a carbonate group. Bonding base.

R ²¹ , R ²² , R ²³ and R ²⁴ each independently represent an alkyl group (preferably having a carbon number of 1 to 20. For example, methyl, ethyl, propyl, isopropyl, butyl, pentyl, Hexyl, heptyl, 2-ethylhexyl, nonyl, decyl), alkoxy (preferably carbon number 1 to 20. For example, methoxy, ethoxy is preferred), aryl (preferably The carbon number is 6 to 20. For example, a phenyl group is preferred, a fluoroalkyl group or an aralkyl group, a hydrocarbon group in which these are combined, or a halogen atom (for example, a fluorine atom is preferred). When R ²² and R ²³ are a polyvalent group, it means a polyvalent hydrocarbon group obtained by removing one or more hydrogen atoms or fluorine atoms from the above-mentioned hydrocarbon group.

In the case where R ²² or R ²³ is bonded to M ¹ , the groups that can be adopted as R ²² or R ²³ may include, in addition to the above-mentioned groups, the above-mentioned hydrocarbon group, or a halogen atom, R ³² and Used imine.

Among the liquid film cleaving agents of the first embodiment, the following compounds are preferred, which have a structure represented by any one of the formulae (1), (2), (5), and (10) as the structure X, And it has a structure represented by any one of the above formulas other than these formulas as the terminal of X, or includes the terminal of X and the base of Y. It is more preferable that the compound contains a siloxane chain having the above-mentioned (2), (4), (5), (6), (8), and the siloxane chain X or a terminal including X and Y And a siloxane chain of at least one of the structures represented by any one of formula (9).

As a specific example of the above-mentioned compound, that is, the liquid film cleaving agent of the first embodiment, an organic modified polysiloxane (polysiloxane) of a polysiloxane-based surfactant can be mentioned. Examples of the organically modified polysiloxane modified with a reactive organic group include amine group modification, epoxy group modification, carboxy group modification, glycol modification, carbinol modification, (meth) propylene Amido modified, mercapto modified, phenol modified. Examples of the non-reactive organic group-modified organic modified polysiloxane include polyether modification (including Polyoxyalkylene modification), methylstyrene-based modification, long-chain alkyl modification, higher fatty acid ester modification, higher alkoxy modification, higher fatty acid modification, fluorine modification, etc. According to the type of these organic modifications, for example, the molecular weight of the polysiloxane chain, the modification ratio, and the added mole number of the modified group can be appropriately changed, so that the expansion coefficient that exerts the cracking effect of the liquid film can be obtained. Here, the "long chain" refers to those having a carbon number of 12 or more, preferably 12 to 20. The term "high-grade" refers to a carbon number of 6 or more, preferably 6 to 20.

Among them, it is used as a liquid film cracking agent of modified polysiloxane such as polyoxyalkylene-modified polysiloxane or epoxy-modified polysiloxane, carbinol-modified polysiloxane, and glycol-modified polysiloxane. A modified polysiloxane having a structure containing at least one oxygen atom in a modified group is preferred, and a polyoxyalkylene-modified polysiloxane is particularly preferred. The polyoxyalkylene-modified polysiloxane has a polysiloxane chain, and when the fiber of the synthetic resin contains a liquid film cleaving agent, it is difficult to penetrate into the fiber and easily remain on the surface. In addition, by adding a polyoxyalkylene chain having a hydrophilic property, the affinity with water is improved, and the interfacial tension is low. Therefore, it is easy to move on the surface of the liquid film, which is preferable. In addition, even if the polyoxyalkylene-modified polysiloxane is subjected to a heat-melting process such as embossing, the liquid film cracking effect that easily remains on the surface of the fiber is not easily weakened. In particular, the embossed portion where the liquid is liable to stagnate sufficiently exhibits the cracking effect of the liquid film, and is therefore preferred.

Examples of the polyoxyalkylene-modified polysiloxane that can be used as the liquid film cleaving agent of the first embodiment include those represented by the following formulas [I] to [IV]. Furthermore, from the viewpoint of the cracking effect of the liquid film, the polyoxyalkylene-modified polysiloxane preferably has a weight average molecular weight within the above range.

[Chemical 4]

In the above formulae [I] to [IV], R ³¹ represents an alkyl group (preferably having 1 to 20 carbon atoms. For example, methyl, ethyl, propyl, isopropyl, butyl, pentyl, and hexyl are preferred , Heptyl, 2-ethylhexyl, nonyl, decyl). R ³² represents a single bond or an alkylene group (preferably having 1 to 20 carbon atoms. For example, methylene, ethylene, propyl, and butylene are preferred), and the above-mentioned alkylene is more preferable. The plurality of R ³¹ and the plurality of R ³² may be the same as or different from each other. M ¹¹ represents a group having a polyoxyalkylene group, and is preferably a polyoxyalkylene group. Examples of the polyoxyalkylene group include a polyoxyethylene group, a polyoxypropylene group, a polyoxybutylene group, or a copolymerized product of these constituent monomers. m and n are each independently an integer of 1 or more. In addition, the symbols of these repeating units are individually determined in each of the formulas [I] to [IV], and do not necessarily represent the same integers, and may be different.

In addition, the polyoxyalkylene-modified polysiloxane that can be used as the liquid film cracking agent of the first embodiment may have one or two modified groups of polyoxyethylene modification and polyoxypropylene modification. By. In addition, in order to be insoluble in water and have a low interfacial tension, it is preferable that the alkyl group R ³¹ of the polysiloxane chain has a methyl group. There is no particular limitation on those having the modified group and the polysiloxane chain. For example, there are those described in paragraphs [0006] and [0012] of Japanese Patent Laid-Open No. 2002-161474. More specifically, polyoxyethylene (POE) polyoxypropylene (POP) modified polysiloxane, or polyoxyethylene (POE) modified polysiloxane, polyoxypropylene (POP) modified polysiloxane Wait. Examples of the POE-modified polysiloxane include POE (3) -modified dimethylpolysiloxane to which 3 Moore of POE is added. Examples of the POP-modified polysiloxane include POP (10) -modified dimethylpolysiloxane and POP (12) -modified dimethylpolysiloxane added with 10 mol, 12 mol, or 24 mol POP. Siloxane, POP (24) modified dimethylpolysiloxane.

Regarding the expansion coefficient and water solubility of the liquid film cracking agent of the first embodiment described above, in the case of polyoxyalkylene modified polysiloxane, for example, the molar number (relative to The polyoxyalkylene-modified polysiloxane has 1 mol of polyoxyalkylene groups and the number of oxyalkylene groups to be bonded, and the following modification ratios are set to specific ranges. The surface tension and interfacial tension of the liquid film cleaving agent can also be set to specific ranges in the same manner.

From the viewpoints described above, the polyoxyalkylene-modified polysiloxane that can be used as the liquid film cleaving agent of the first embodiment is preferably one in which the addition mole number of the polyoxyalkylene is 1 or more. From the viewpoint of increasing the expansion coefficient by reducing the interfacial tension and thereby enhancing the cracking effect of the liquid film, the number of added moles is more preferably 3 or more, and even more preferably 5 or more. On the other hand, it prevents the water from becoming hydrophilic and the water solubility is too high. From a viewpoint, the addition mole number is preferably 30 or less, more preferably 20 or less, and even more preferably 10 or less.

Regarding the modification rate of the modified polysiloxane, in order to ensure necessary hydrophilicity, it is preferably 5% or more, more preferably 10% or more, and still more preferably 20% or more. In order to make it insoluble in water, it is preferably 95% or less, more preferably 70% or less, and even more preferably 40% or less. In addition, the so-called modification rate of the modified polysiloxane is the number of repeating units of the modified siloxane bond in the modified polysiloxane 1 with respect to the repetition of the siloxane bond. The ratio of the total number of units. For example, (n / m + n) × 100% in the above formulas [I] and [IV], (2 / m) × 100% in the formula [II], and (1 / m) in the formula [III]. × 100%.

In addition, regarding the above-mentioned expansion coefficient and water solubility, in the case of polyoxyalkylene-modified polysiloxane, each of them can be set to a specific range by the following methods in addition to the above methods, that is, as a modified group Water-soluble polyoxyethylene group and water-insoluble polyoxypropylene group and polyoxybutene group; change the molecular weight of water-insoluble polysiloxane chain; as a modification group, in addition to polyoxyalkylene modification, An amine group, an epoxy group, a carboxyl group, a hydroxyl group, a carbinol group, and the like are introduced.

When the non-woven fabric contains polyalkylene-modified polysiloxane that can be used as the liquid film cleaving agent of the first embodiment, the content ratio (Oil Per Unit (oil content)) with respect to the fiber mass is more than The content is preferably 0.02% by mass or more and 8% by mass or less. The content ratio (OPU) of the polyalkylene-modified polysiloxane is preferably 5 mass% or less, more preferably 1 mass% or less, and even more preferably 0.4 mass% or less. By doing so, the touch of the non-woven fabric is good. From the viewpoint of fully exerting the cracking effect of the liquid film generated by the polyalkylene-modified polysiloxane, the content ratio (OPU) is more preferably 0.0005 mass% or more, and still more preferably 0.0015 mass% or more.

In addition, not limited to non-woven fabrics, the content of the polyalkylene-modified polysiloxane contained in the physiological article is preferably 0.00001 g / m ² or more, and more preferably 0.0001 g from the viewpoint of acting on the liquid film. / m ² or more, more preferably 0.0003 g / m ² or more. In addition, the content of the polyalkylene-modified polysiloxane contained in a physiological article is preferably 10 g / m ² or less, more preferably 7 g / m ² or less, from the viewpoint of ensuring liquid permeability. It is 5 g / m ² or less. Specifically, the content of the polyalkylene-modified polysiloxane as the liquid film cracking agent of the first embodiment contained in the physiological article is preferably 0.00001 g / m ² or more and 10 g / m ² or less, and more preferably of 0.0001g / m ² or more and 7g / m ² or less, further preferably 0.0003g / m ² or more and 5g / m ² or less.

As the liquid film cleaving agent of the second embodiment, a compound having at least one structure selected from the group consisting of the following structures Z, Z-Y, and Y-Z-Y is described below. The structures Z and Y mentioned here are specifically the following structures. In the following structures, "C" represents a carbon atom, and "<", ">", and "-" each represent a bond.

Structure Z means> C (A)-, -C (A) _2- , -C (A) (B)-,> C (A) -C (R ³ ) <,> C (R ³ )-,- C (R ³ ) (R ⁴ )-, -C (R ³ ) ₂ -,> C <Any one of the basic structure repeats or a combination of two or more types of hydrocarbon chain structure. At the end of structure Z has a member selected from the group consisting of a hydrogen atom, or -C (A) ₃ , -C (A) ₂ B, -C (A) (B) _2, -C (A) ₂ -C (R ³ ) ₃ At least one type of group consisting of -C (R ³ ) ₂ A, -C (R ³ ) ₃ .

Each of the above R ³ or R ⁴ independently represents a hydrogen atom or an alkyl group (preferably having a carbon number of 1 to 20. For example, methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl, Heptyl, 2-ethylhexyl, nonyl, decyl), alkoxy (preferably carbon number 1 to 20. For example, methoxy, ethoxy group is preferred), aryl (preferably carbon number 6 to 20. For example, a phenyl group), a fluoroalkyl group, an aralkyl group, or a hydrocarbon group in which these are combined, or various substituents such as a fluorine atom are preferred. A and B each independently represent a substituent including an oxygen atom or a nitrogen atom such as a hydroxy group or a carboxylic acid group, an amine group, an amidino group, an imino group, or a phenol group. When there are a plurality of R ³ , R ⁴ , A, and B in the structure Z, these may be the same as or different from each other. In addition, the continuous bond between C (carbon atom) is usually a single bond, but it may also include a double bond or a triple bond. The bond between C may also include an ether group, amidino group, ester group, carbonyl group, carbonate group, etc. Linker. The number of one C and other C bonds is 1 to 4, and there may be cases where the long-chain hydrocarbon chain has branches or has a radial structure.

The structure Y represents a hydrophilic group containing an atom selected from the group consisting of a hydrogen atom, a carbon atom, an oxygen atom, a nitrogen atom, a phosphorus atom, and a sulfur atom and having hydrophilicity. For example, it is a hydroxyl group, a carboxylic acid group, an amine group, an amido group, an imine group, a phenol group, or a polyoxyalkylene group (the carbon number of the oxyalkylene group is preferably 1 to 4. For example, polyoxyethylene is preferred (Polyoxypropylene, polyoxybutenyl, or polyoxyalkylene in combination), or erythritol, xylitol, sorbitol, glyceryl, glycol Hydrophilic groups having a plurality of hydroxyl groups, or sulfonic acid groups, sulfuric acid groups, phosphate groups, sulfobetaines, carbonyl betaines, phosphate betaines, quaternary ammonium groups, imidazolium betaines, epoxy A hydrophilic group alone, or a hydrophilic group containing a combination thereof among methyl, carbinol, methacryl, and the like. When Y is plural, they may be the same as or different from each other.

In the structures Z-Y and Y-Z-Y, Y is bonded to Z or a terminal group of Z. In the case where Y is bonded to a radical at the end of Z, the radical at the end of Z is bonded to Y, for example, by removing hydrogen atoms whose number is equal to the number of bonds to Y.

In this structure, the hydrophilic groups Y, A, and B can be selected from the specified bases to satisfy the aforementioned expansion coefficient, water solubility, and interfacial tension. This shows the target liquid film cracking effect.

The liquid film cleaving agent of the second embodiment is preferably a compound obtained by arbitrarily combining the structures represented by the following formulae (12) to (25) as specific examples of the structures Z, Z-Y, and Y-Z-Y. Furthermore, it is preferable that this compound has a weight average molecular weight of the said range from a viewpoint of a liquid film cracking effect.

[Chemical 8]

In the formulae (12) to (25), M ² , L ² , R ⁴¹ , R ⁴² , and R ⁴³ represent the following monovalent or polyvalent group (divalent or higher).

M ² represents a group having a polyoxyethylene group, a polyoxypropylene group, a polyoxybutenyl group, or a combination of these polyoxyalkylene groups, or an erythritol group, a xylitol group, and a sorbitol group , Glyceryl or ethylene glycol-containing hydrophilic groups having a plurality of hydroxyl groups, hydroxyl group, carboxylic acid group, mercapto group, alkoxy group (preferably carbon number 1-20. For example, methoxy group is preferred), amino group, Amido, imino, phenol, sulfonic, quaternary ammonium, sulfobetaine, hydroxysulfobetaine, phosphobetaine, imidazolium betaine, carbonyl betaine, An epoxy group, a carbinol group, a (meth) acryl group, or a functional group combining these.

L ² represents an ether group, an amine group, an amine group, an ester group, a carbonyl group, a carbonate group, or a polyoxyethylene group, a polyoxypropylene group, a polyoxybutenyl group, or a polyoxyalkylene group in combination of these, etc. Bonding base.

R ⁴¹ , R ^42, and R ⁴³ each independently include a hydrogen atom and an alkyl group (preferably having 1 to 20 carbon atoms. For example, methyl, ethyl, propyl, isopropyl, butyl, and pentyl are preferred , Hexyl, heptyl, 2-ethylhexyl, nonyl, decyl), alkoxy (preferably carbon number 1-20. For example, methoxy, ethoxy is preferred), aryl (preferably The number of carbon atoms is 6 to 20. For example, a phenyl group), a fluoroalkyl group, an aralkyl group, or a hydrocarbon group or a halogen atom (for example, a fluorine atom) is preferably used in combination.

When R ⁴² is a polyvalent group, R ⁴² represents a group obtained by removing one or more hydrogen atoms from each of the above substituents.

In addition, the end of the bond described in each structure may be arbitrarily connected to another structure or introduce a hydrogen atom.

Furthermore, as specific examples of the above-mentioned compound, which is the liquid film cleaving agent of the second embodiment, firstly, polyether compounds and nonionic surfactants may be mentioned, and secondly, hydrocarbon compounds having 5 or more carbon atoms may be mentioned. Not limited to these.

Specific examples of the polyether compound and the nonionic surfactant as the first specific example of the liquid film cleaving agent of the second embodiment include polyoxygen represented by any one of the following formula [V] Polyalkylene oxide (POA) ether, or polyoxyalkylene glycol having a weight average molecular weight of 1,000 or more represented by the following formula [VI], stearyl polyether, behenyl polyether, and PPG myristyl ether , PPG stearyl ether, PPG behenyl ether, etc. As the polyoxyalkylene alkyl ether, a lauryl ether to which POP of 3 mol or more and 24 mol or less, more preferably 5 mol is added is preferable. As the polyether compound, polypropylene glycol having a weight-average molecular weight of 1,000 to 10,000, preferably 3000 to 17 mol or more and 180 mol or less, and preferably 3,000 or more is preferable. The measurement of the weight average molecular weight can be performed by the following measurement method.

When the non-woven fabric contains a polyether compound or a nonionic surfactant that can be used as a liquid film cleaving agent in the second embodiment, it is preferably 0.1 in terms of the content ratio (Oil Per Unit) to the fiber mass. Above mass% and below 8 mass%. The content ratio (OPU) of the polyether compound or non-ionic surfactant is more preferably 5% by mass or less, and further preferably 1.0% by mass or less. Especially preferably, it is 0.4 mass% or less. By doing so, the touch of the non-woven fabric is good. From the viewpoint of sufficiently exerting the cracking effect of the liquid film by the polyether compound or the nonionic surfactant, the content ratio (OPU) is more preferably 0.0005 mass% or more, and still more preferably 0.0015 mass% or more.

In addition, not limited to non-woven fabrics, the content of the polyether compound or non-ionic surfactant contained in the physiological article is preferably 0.00001 g / m ² or more, and more preferably 0.0001 g from the viewpoint of reliably acting on the liquid film. / m ² or more, more preferably 0.0003 g / m ² or more. In addition, the content of the polyether compound or the nonionic surfactant contained in the physiological article is preferably 10 g / m ² or less, more preferably 7 g / m ² or less, and more preferably from the viewpoint of ensuring liquid permeability. It is 5 g / m ² or less. Specifically, the content of the polyether compound or the non-ionic surfactant contained in the physiological article as the liquid film cleaving agent of the second embodiment is preferably 0.00001 g / m ² or more and 10 g / m ² or less, and more preferably of 0.0001g / m ² or more and 7g / m ² or less, further preferably 0.0003g / m ² or more and 5g / m ² or less.

In the above formula [V], L ²¹ represents an ether group, an amine group, an amidine group, an ester group, a carbonyl group, a carbonate group, a polyoxyethylene group, a polyoxypropylene group, a polyoxybutene group, or a combination of these. Bonding groups such as polyoxyalkylene. In the formulae [V] and [VI], R ⁵¹ represents a hydrogen atom, a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, a pentyl group, a hexyl group, a heptyl group, a 2-ethylhexyl group, and a nonyl group. , A decyl group, a methoxy group, an ethoxy group, a phenyl group, a fluoroalkyl group, an aralkyl group, or a hydrocarbon group or a variety of substituents including a fluorine atom in combination. In addition, a, b, m, and n are each independently an integer of 1 or more. Here, C _m H _n represents an alkyl group (n = 2m + 1), and C _a H _b represents an alkylene group (a = 2b). In addition, the number of these carbon atoms and the number of hydrogen atoms is determined independently in each of the formulas [V] and [VI], and does not necessarily represent the same integer, and may be different. The same applies to m, m ', m ", n, n', and n" in the following formulas [VII] to [XV]. The "m" of-(C _a H _b O) _m -is an integer of 1 or more. The value of the repeating unit is determined independently in each of the formulas [V] and [VI], and does not necessarily represent the same integer, and may be different.

Regarding the expansion coefficient, surface tension, and water solubility of the liquid film cleaving agent in the second embodiment, in the case of a polyether compound or a nonionic surfactant, for example, the molar number of polyoxyalkylene can be used to determine Set each to a specific range. From this viewpoint, the molar number of the polyoxyalkylene group is preferably 1 or more and 70 or less. From the viewpoint of increasing the expansion coefficient by reducing the interfacial tension and thereby enhancing the cracking effect of the liquid film, the Mohr number is more preferably 5 or more, and even more preferably 7 or more. On the other hand, from the viewpoint of preventing the molecular chain entanglement from becoming too strong and reducing the diffusibility in the liquid film, the addition mole number is preferably 70 or less, more preferably 60 or less, and even more preferably 50. the following.

In addition, regarding the above-mentioned expansion coefficient, surface tension, interfacial tension, and water solubility, in the case of a polyether compound or a non-ionic surfactant, each can be set to a specific range by using water-soluble polyoxygen in combination. Vinyl and water-insoluble polyoxypropylene and polyoxybutenyl groups change the chain length of the hydrocarbon chain. They are used for those with branched chains on the hydrocarbon chain, those with double bonds on the hydrocarbon chain, and those on the hydrocarbon chain. Those having a benzene ring or a naphthalene ring, or a combination of the above-mentioned methods as appropriate.

Hydrocarbon having 5 or more carbon atoms as a second specific example of the liquid film cracking agent of the second embodiment The compounds are explained. From the viewpoint that the liquid is more likely to expand on the surface of the liquid film, the number of carbon atoms of the hydrocarbon compound is preferably 100 or less, and more preferably 50 or less. The hydrocarbon compound does not include a polyorganosiloxane, and is not limited to a straight chain, and may be a branched chain, and the chain is not particularly limited to saturated and unsaturated. Moreover, it may have substituents, such as an ester and an ether, in the middle and a terminal. Among them, those which are liquid at normal temperature can be used alone. When the non-woven fabric contains the hydrocarbon compound, it is preferably contained in an amount of 0.1% by mass to 5% by mass in terms of a content ratio (Oil Per Unit) with respect to the mass of the fiber. The content ratio (OPU) of the hydrocarbon compound is preferably 1% by mass or less, more preferably 0.99% by mass or less, and still more preferably 0.4% by mass or less. By doing so, the touch of the non-woven fabric is good. From the viewpoint of sufficiently exerting the cracking effect of the liquid film by the hydrocarbon compound, the content ratio (OPU) is more preferably 0.0005 mass% or more, and still more preferably 0.0015 mass% or more.

In addition, it is not limited to non-woven fabrics, and the content of the hydrocarbon compound having 5 or more carbon atoms contained in the physiological article is preferably 0.00001 g / m ² or more, more preferably 0.0001 g / m ² or more, more preferably 0.0003 g / m ² or more. In addition, the content of the hydrocarbon compound having 5 or more carbon atoms in the physiological article is preferably 10 g / m ² or less, more preferably 7 g / m ² or less, and more preferably from the viewpoint of not impairing liquid permeability. 5g / m ² or less. Specifically, the content of the hydrocarbon compound having 5 or more carbon atoms as the liquid film cleaving agent of the second embodiment contained in the physiological article is preferably 0.00001 g / m ² or more and 10 g / m ² or less, and more preferably 0.0001g / m ² or more and 7g / m ² or less, further preferably 0.0003g / m ² or more and 5g / m ² or less.

Examples of the hydrocarbon compound usable as the liquid film cracking agent in the second embodiment include oils and fats, such as natural oils and natural fats. Specific examples include coconut oil, camellia oil, castor oil, coconut oil, corn oil, olive oil, sunflower oil, tall oil, and mixtures thereof.

Examples of the hydrocarbon compound usable as the liquid film cracking agent in the second embodiment include: Acids, capric acid, oleic acid, lauric acid, palmitic acid, stearic acid, myristic acid, behenic acid, and mixtures thereof are the fatty acids represented by the following formula [VII].

[Formula _{11] C m H n -COOH [} VII]

In the formula [VII], m and n are each independently an integer of 1 or more. Here, C _m H _n represents a hydrocarbon group of each of the aforementioned fatty acids.

Specific examples of the hydrocarbon compound (fatty acid) that can be used as the liquid film cleaving agent of the second embodiment include linear or branched chain, saturated or unsaturated, substituted or unsubstituted polyhydric alcohol fatty acid esters, or polyhydric alcohols. Examples of the mixture of alcohol fatty acid esters include glycerol fatty acid esters or pentaerythritol fatty acid esters represented by the following formula [VIII-I] or [VIII-II], and specific examples include tricaprylycerin Acid esters, glycerol tripalmitate, and mixtures thereof. In addition, glycerin fatty acid esters or pentaerythritol fatty acid ester mixtures typically include some mono-, di-, and tri-esters. Preferred examples of the glycerin fatty acid ester include glycerol tricaprylate, a mixture of glycerol tricaprylate, and the like. Moreover, from the viewpoint of reducing the interfacial tension and obtaining a higher expansion coefficient, a polyhydric alcohol fatty acid ester having a polyoxyalkylene group introduced to such an extent that it can maintain water insolubility can also be used.

[Chemical 13]

In the formulae [VIII-I] and [VIII-II], m, m ', m ", n, n', and n" are each independently an integer of 1 or more. The plurality of m and the plurality of n may be the same as or different from each other. Here, C _m H _n , C _m 'H _n ' and C _m "H _n " each represent a hydrocarbon group of each of the aforementioned fatty acids.

Specific examples of the hydrocarbon compound (fatty acid) that can be used as the liquid film cleaving agent of the second embodiment include linear or branched saturated or unsaturated fatty acids that form esters with polyhydric alcohols having a plurality of hydroxyl groups, and a part of them The fatty acid or fatty acid mixture remaining without esterification of the hydroxyl group may be exemplified by any one of the following formula [IX], any one of the following formula [X], or the following formula [XI] A glycerin fatty acid ester, a partial esterified product of a sorbitan fatty acid ester, or a pentaerythritol fatty acid ester represented by any one of them. Specific examples include ethylene glycol monomyristate, ethylene glycol dimyristate, ethylene glycol palmitate, ethylene glycol dipalmitate, glycerol dimyristate, and glycerol dipalmitate. Esters, glycerol monooleate, sorbitan monooleate, sorbitan monostearate, sorbitan dioleate, sorbitan tristearate, pentaerythritol monostearate, Pentaerythritol dilaurate, pentaerythritol tristearate, and mixtures thereof. In addition, a mixture containing partially esterified products such as glycerin fatty acid esters, sorbitan fatty acid esters, pentaerythritol fatty acid esters and the like typically contains some fully esterified compounds.

[Chemical 14]

In the formula [IX], m and n are each independently an integer of 1 or more. The plurality of m and the plurality of n may be the same as or different from each other. Here, C _m H _n represents a hydrocarbon group of each of the aforementioned fatty acids.

In the formula [X], R ⁵² represents a straight or branched chain saturated or unsaturated hydrocarbon group (alkyl, alkenyl, alkynyl, etc.) having 2 or more and 22 or less carbon atoms. Specific examples include 2-ethylhexyl, lauryl, myristyl, palmyl, stearyl, behenyl, oleyl, and linoleyl.

[Chemical 16]

In the formula [XI], m and n are each independently an integer of 1 or more. The plurality of m and the plurality of n may be the same as or different from each other. Here, C _m H _n represents a hydrocarbon group of each of the aforementioned fatty acids.

Examples of the hydrocarbon compound that can be used as the liquid film cleaving agent in the second embodiment include sterols, phytosterols, and sterol derivatives. Specific examples include cholesterol, sterol, stigmasterol, ergosterol, and mixtures thereof having a sterol structure of the following formula [XII].

Examples of the hydrocarbon compound that can be used as the liquid film cleaving agent in the second embodiment include alcohols. Specific examples of the alcohol include lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, cetylstearyl alcohol, behenyl alcohol, and mixtures thereof as shown in the following formula [XIII].

[Formula _{18] C m H n -OH [} XIII]

In the formula [XIII], m and n are each independently an integer of 1 or more. Here, C _m H _n represents a hydrocarbon group of each of the aforementioned alcohols.

Specific examples of the fatty acid ester that can be used as the liquid film cleaving agent of the second embodiment include isopropyl myristate, isopropyl palmitate, and ethylhexanoic acid whale represented by the following formula [XIV] Wax esters, glyceryl triisocaprylate, octyldodecyl myristate, ethylhexyl palmitate, ethylhexyl stearate, butyl stearate, myristyl myristate, stearic acid Stearyl ester, cholesterol isostearate, and mixtures thereof.

[Chemical Formula _{19] C m H n -COO-} C m H n [XIV]

In the formula [XIV], m and n are each independently an integer of 1 or more. Here, the two C _m H _n may be the same or different. C _m H _n -COO- C _m H _n denotes the above-mentioned hydrocarbon group for each of the fatty acid. -COO-C _m H _n C _m H _n represents the hydrocarbon group of the alcohol esters derived form.

Moreover, as a compound which can be used as the liquid film cracking agent of 2nd Embodiment, a wax is mentioned. Specific examples of the wax include terrestrial wax, paraffin wax, petrolatum, mineral oil, liquid isoparaffin, and the like represented by the following formula [XV].

[Chem. 20] C _m H _n [XV]

In the formula [XV], m and n are each independently an integer of 1 or more.

Regarding the expansion coefficient, surface tension, water solubility, and interfacial tension of the liquid film cleaving agent of the second embodiment, in the case of the above-mentioned hydrocarbon compound having 5 or more carbon atoms, the specific ranges can be set by the following methods, For example, a small amount of hydrophilic polyoxyethylene group can be introduced to maintain water insolubility, and a polyoxypropylene group or polyoxybutylene group which can reduce the interfacial tension, although hydrophobic, can be introduced to change the chain length of the hydrocarbon chain. Those having a branched hydrocarbon chain, those having a double bond on the hydrocarbon chain, those having a benzene ring or a naphthalene ring on the hydrocarbon chain, and the like.

The physiological article of the present invention has the above-mentioned liquid-film-cracking agent-containing liquid-film-cracking agent region, and the liquid-film-cracking agent-containing region or other regions may contain other components in addition to the liquid-film-cracking agent as necessary. In addition, one of the liquid film cleaving agent of the first embodiment and the liquid film cleaving agent of the second embodiment may be used, or the two types of agents may be used in combination. In the latter case, one Two agents are mixed in the area of the liquid film-cracking agent. The same applies to the first and second specific examples of the liquid film cleaving agent of the second embodiment.

(Basic composition of physiological products)

As described above, the physiological article of the present invention has an absorbent body, and a front sheet can be arranged on the skin abutting surface side, and a back sheet can be arranged on the non-skin abutting surface side of the absorbent body. The back sheet may be liquid-impermeable, liquid-impermeable or water-repellent. A liquid-permeable sheet called a second sheet may be disposed between the front sheet and the absorber. In the case of a physiological article such as a menstrual tampon, the menstrual tampon generally has a lengthwise direction having a length direction and a width direction orthogonal to the lengthwise direction. shape. On the abutment surface of the menstrual pad, a pair of leak-proof flanging extending in the length direction can be arranged on both sides in the width direction. The leak-proof flanging has a standing property on the skin side of the user of a menstrual tampon, thereby preventing the leakage of menstrual blood excreted on the abutment surface of the tampon.

The absorbent body preferably contains a superabsorbent polymer. In addition to the superabsorbent polymer, it may also include an absorbent fibrous material instead. Alternatively, the absorber may be composed of only a superabsorbent polymer. A typical example of the absorbent body is a member that is also called an absorbent core material that is usually contained in such a physiological article. Specifically, for example, a staple fiber pulp containing wood pulp, and a synthetic fiber that has been hydrophilized may be cited. A fiber material and a particulate superabsorbent polymer. In the absorbent core material of this structure, the superabsorbent polymer is usually held in the aggregate of the fibrous material by the adhesive force generated by the superabsorbent polymer in a wet state or by an additional adhesive such as an adhesive or an adhesive fiber. in. The absorptive core material may be a fiber stack in which a short fiber pulp and a super absorbent polymer are mixed, and the short fiber pulp and the super absorbent polymer in the fiber stack may be uniformly mixed, or unevenly mixed, or These materials have different local basis weights.

As the superabsorbent polymer used in the present invention, a liquid capable of absorbing and maintaining at least 20 times its own weight and capable of gelling is preferred. Examples of such superabsorbent polymers include starch or croscarmellose, polymers or copolymers of acrylic acid or alkali metal salts of acrylic acid, polyacrylic acid and its salts, and polyacrylate grafting. polymer. As the polyacrylate, a sodium salt can be preferably used.

The absorbent body may have an absorptive core material and a covered core material. The core material may be not only a form that covers the entire absorptive core material, but also a form that is only partially covered by the skin abutment surface side covering the absorptive core material, for example. In the present invention, the so-called absorptive system includes the concept of an absorptive core material and an optionally-used core material. The core material can be crepe paper or spunbond-meltblown-spunbond (SMS) nonwoven fabric.

The front sheet is not particularly limited as long as it is a liquid-permeable sheet. For example, a well-known material in the field such as a hot air nonwoven fabric, a spunbond nonwoven fabric, and a spunlace nonwoven fabric can be arbitrarily used. These nonwoven fabrics can be formed by using fibers made of resins such as polyethylene, polypropylene, and polyethylene terephthalate. It is preferable to apply a hydrophilic fiber treatment agent to these fibers. The front sheet may include one layer or a plurality of layers. In addition, the front sheet may be flat on the skin-contacting surface or non-skin-contacting surface, or may be non-flatness in which either or both surfaces have unevenness, or may cause the basis weight or density of the fibers to be generated. Various changers. When the front sheet includes a plurality of layers, the blood cell agglutinating agent and the liquid film cleaving agent may be contained in all the layers, or may be contained in a part of the layers.

When the back sheet is liquid-permeable, the same one as the front sheet can be used. When the back sheet is liquid-impermeable, liquid-impermeable or water-repellent, a spunbond nonwoven fabric, an SMS nonwoven fabric, or a moisture-permeable film can be used, or a laminate of a nonwoven fabric and a moisture-permeable film can be used. .

5 and 6 show a menstrual tampon 10 as one embodiment of the physiological article of the present invention. The menstrual tampon 10 has a longitudinal direction X corresponding to the front and back direction of the user and a transverse direction Y orthogonal to the user. As shown in FIG. 5, the longitudinal length of the longitudinal direction X is greater than the longitudinal direction Y Long shape.

Menstrual tampon 10 is provided with a liquid-permeable front sheet 20 which forms the skin abutment surface of menstrual tampon 10, a water-repellent back sheet 30 which forms a non-skin abutment surface of menstrual tampon 10, and an intervening sheet The liquid-retaining absorber 40 between the sheets 20 and 30 is integrated by a known bonding method such as an adhesive. The front sheet 20 and the back sheet 30 are respectively extended from the peripheral edge of the absorber 40, and end portions of these extended portions are bonded to each other by a known bonding method such as an adhesive or heat sealing to form an end seal portion 50. A leak-proof groove 60 having a ring shape in a plan view is formed on the skin abutment surface of the menstrual napkin 10 in which the front sheet 20 and the absorber 40 are integrally recessed. During menstruation A pair of side sheets 70 and 70 are arranged on the left and right sides of the skin abutment surface of the sanitary napkin 10 along the longitudinal direction X of the menstrual napkin 10 over the entire length of the longitudinal direction X of the menstrual napkin 10. The absorbent body 40 is comprised by the liquid-retaining absorptive core material 41, and the core material 42 which covers both the skin contact surface and non-skin contact surface which coat | covers this absorptive core material 41. The absorbent core material 41 includes a fibrous material and a particulate highly absorbent polymer.

FIG. 7 shows a front sheet 20 included in the menstrual tampon 10. In the front sheet 20, the first surface 20A side which is the skin contact surface is uneven, and the second surface 20B side which is the non-skin contact surface is flat or uneven, but the degree of unevenness is compared with the first surface 20A side. Very small. Specifically, the uneven shape on the first surface 20A side includes a plurality of convex portions 21 and linear concave portions 22 surrounding the convex portions 21. Each of the plurality of convex portions 21 bulges to the first surface 20A side. The linear concave portions 22 are arranged in a grid pattern. The first surface 20A of the front sheet 20 is divided into a plurality of regions by the concave portions 22 arranged in a grid pattern. One convex portion 21 is arranged in each of the regions. That is, a plurality of convex portions 21 are arranged on the first surface 20A of the front sheet 20 which is the skin contact surface.

The front sheet 20 includes heat-extensible fibers whose length is extended by heating. Examples of the heat-extensible fiber include a fiber that is elongated by changing the crystalline state of the resin by heating, or a fiber that has been subjected to a crimping process and is heated to eliminate the crimp to extend the appearance length. If a fibrous web composed mainly of unheated heat-extensible fibers as a manufacturing intermediate of the front sheet 20 is formed into a grid-like recessed portion 22 by embossing or the like, heat treatment such as hot-air processing such as blowing hot air is performed, Then, the heat-extensible fiber existing in each region divided by the recessed portion 22 is stretched, whereby each region becomes fluffier than the recessed portion 22. The fluffy portion thus formed is a convex portion 21. Due to the manufacturing steps of the front sheet 20, the convex portion 21 is a solid structure filled with constituent fibers, but it is a fluffy portion with a relatively low fiber density compared with the concave portion 22. On the other hand, the recessed portion 22 has a crimped portion where the constituent fibers of the front sheet 20 are crimped or bonded, and the heat-extensible fibers present in the recessed portion 22 Since the thermal elongation is impaired due to pressure bonding, it is in a non-elongated state even if it undergoes heat treatment.

The front sheet 20 has a double-layer structure including an upper layer on the first surface 20A side and a lower layer on the second surface 20B side. The upper layer on the first surface 20A side is a layer having a concave-convex shape including the convex portion 21 and is mainly composed of a heat-extensible fiber. The proportion of the heat-extensible fiber in all the constituent fibers of the upper layer is preferably 30% by mass or more, more preferably 50% by mass or more, still more preferably 100% by mass or less, and even more preferably 80% by mass or less. On the other hand, the lower layer on the second surface 20B side does not contain a heat-extensible fiber, or the content of the heat-extensible fiber is smaller than that of the upper layer on the first surface 20A side having an uneven shape. The two layers constituting the front sheet 20 are preferably joined to each other by a pressing portion of the recessed portion 22. The front sheet 20 is not limited to a double-layer structure, and may be a single-layer structure or a multi-layer structure having three or more layers.

By using such a front-face sheet 20 having a concave-convex shape, the contact area with the user's skin is controlled to effectively prevent stuffiness or skin rash. In addition, the convex portion 21 contacting the skin becomes fluffy due to the thermal extension of the heat-extensible fiber, and the skin feels soft.

The front sheet 20 can be manufactured by the following method, for example. First, a linear web-shaped recessed portion 22 is formed on a fiber web including heat-extensible fibers by heat embossing. At this time, in the recessed portion 22, the heat-extensible fiber is crimped or fused, and is fixed without thermal elongation. Then, hot-air processing was performed on the fiber web. As a result, the heat-extensible fibers existing in the portion other than the recessed portion 22, that is, in the area surrounded by the lattice-shaped recessed portion 22, bulge toward the first surface 20A side, thereby forming the protruding portion 21, thereby becoming a front sheet材 20。 20. As the constituent fibers of the front sheet 20, only heat-extensible fibers may be used, or in addition to heat-extensible fibers, non-heat-extensible heat-adhesive fibers may be used. As the constituent fibers of the front sheet 20, for example, those described in paragraphs [0013], [0037] to [0040] of Japanese Patent Laid-Open No. 2005-350836, and paragraphs of Japanese Patent Laid-Open No. 2011-1277258 can be used. [0012], [0024] to [0046], and others.

(Hemagglutination-containing area and liquid-film-splitting area)

The inventors have found that by using a blood agglutinating agent in the physiological article and also using a liquid film cracking agent, the whiteness of the surface of the physiological article after use can be maintained. Furthermore, it was found that, as described below, the amount of liquid returned was significantly reduced when the combination was used, compared with the case where only the hemagglutinating agent was used and the case where only the liquid film cleavage agent was used. This phenomenon will be described by taking, as an example, the configuration of the menstrual tampon 10.

First, a menstrual tampon (hereinafter referred to as a menstrual tampon 10A) is provided with a hemagglutinating agent-containing area and no liquid film-splitting agent-containing area on the core material 42 on the skin abutting surface side of the absorbent core material 41 Be explained. Menstrual tampon 10A does not contain liquid film cracking agents, and is a physiological product outside the scope of the present invention.

When blood is excreted to the menstrual pad 10A, the blood that has reached the hemagglutinating agent-containing region of the encapsulating material 42 starts to form a red blood cell agglutination at that position, and is separated from the plasma components. In this way, like filtering at the gap in the absorbent body 40, the red blood cell agglomerates are held on the skin abutment surface side of the absorbent body 40, and the plasma components gradually diffuse into the absorbent body. Furthermore, the plasma component reaches the non-skin contact surface side in the absorber 40, and is mainly held on the non-skin contact surface side of the absorbent core material 41. The liquid containing the plasma component held here tends to flow back to the skin contact surface side when the menstrual pad 10A is pressed, etc., but the red blood cell agglomerates existing on the skin contact surface side of the absorber 40 Obstacles make it difficult to reach the front sheet 20. This reduces the amount of liquid returned.

However, since the menstrual napkin 10A forms a red blood cell agglomerate near the front sheet 20, there is room for improvement in the appearance seen from the skin abutting surface side after use.

Next, a menstrual tampon (hereinafter referred to as a menstrual tampon 10B) provided with a liquid film cleaving agent-containing region and no hemagglutinating agent-containing region on the front sheet 20 will be described. Menstrual tampon 10B does not contain a blood agglutinating agent and is a physiological product outside the scope of the present invention.

If blood is excreted to the menstrual napkin 10B, the blood reaching the area of the liquid film lysing agent of the front sheet 20 will be pushed away by the liquid film lysing agent to destabilize the liquid film. A liquid film is continuously formed in the front sheet 20 and flows to the absorber 40 due to its own weight. Thereby, in the absorber 40, blood, and more specifically, blood passing through the liquid-film-containing cleaving agent region, spreads in a planar direction while flowing from the skin abutting surface side to the non-skin abutting surface side. As a result, in the absorber 40, the blood diffusion area on the non-skin contact surface side is larger than the blood diffusion area on the skin contact surface side. Therefore, the effect that the liquid is not retained in the front sheet 20 and the effect that the diffusion area on the skin abutment surface side of the absorber 40 is small complementarily, and the surface whiteness of the menstrual napkin 10B after use becomes extremely excellent . In addition, since there is no liquid film in the region from the absorbent body 40 to the skin abutting surface side of the front sheet 20, it is difficult to form a liquid passage and reduce the amount of liquid return.

However, compared with menstrual tampon 10B without a blood agglutinating agent, menstrual tampon 10A with a blood agglutinating agent tends to return to the skin abutment surface side when the pressure is applied to the absorbent body when pressure is applied, etc. The red blood cell agglutination existing on the skin abutting surface side is not easy to return to the surface layer, so the amount of liquid returned is small, so there is room for improvement in the blood absorption performance of menstrual cotton 10B.

The physiological article of the present invention contains two doses with respect to menstrual tampons 10A and 10B containing only one of a blood cell agglutinating agent and a liquid film dehiscence agent. Further, the physiological article of the present invention is provided with a blood cell agglutinating agent region containing a blood cell agglutinating agent and a liquid film cleaving agent region containing a liquid film cleaving agent, and the positions of the two regions are located at or more than the absorbent body. The skin abuts the face side. By arranging a blood cell agglutinating agent region and a liquid film cleaving agent region closer to the skin abutting surface side than the absorbent body, it is possible to make full use of these effects to reduce the amount of liquid return and the surface whiteness after use. The improvement effect.

As a first embodiment of the physiological article of the present invention, a blood cell agglutinating agent and a liquid film cleaving agent are mixedly disposed in the core material 42 on the skin abutment surface side of the absorbent core material 41. That is, a menstrual tampon (hereinafter referred to as a menstrual tampon 10C) in which the blood cell agglutinating agent-containing region and the liquid film-splitting agent-containing region overlap in both the thickness direction and the planar direction.

When the blood is excreted into the menstrual napkin 10C, and the blood reaches the encapsulating material 42, the blood cannot be continuously formed into a liquid film by the effect of the liquid film cracking agent, and is quickly introduced into the absorbent core material 41. At the same time, red blood cell agglomerates are gradually formed by the effect of the blood cell agglutinating agent. The formed red blood cell agglomerates can no longer pass through the voids in the absorptive core material 41, and are thus held in the mid-abdomen in the thickness direction of the absorbent body 40. On the other hand, the plasma component in the blood further diffuses to the non-skin contact surface side of the absorbent core material 41 and is held there. During this entire process, blood that has passed through the area containing the liquid film lysing agent diffuses in a planar direction. As a result, in the absorber 40, the blood diffusion area on the non-skin contact surface side is larger than the blood diffusion area on the skin contact surface side.

According to the above phenomenon, first, regarding the amount of liquid returned, the liquid held on the non-skin contact surface side of the absorber 40 is blocked by the red blood cell agglutination and cannot easily move to the skin contact surface side. In addition, since no liquid film is formed in the chip material 42, it is difficult to form a liquid passage to the front sheet 20. With the above complementary effects, the liquid return volume of menstrual tampon 10C is significantly reduced compared with menstrual tampon 10A and menstrual tampon 10B.

Secondly, as for the whiteness of the surface, since the red blood cell agglomerates are held in the mid-abdomen in the thickness direction of the absorber 40, it is not easy to appear through the front sheet 20 side. In addition, since the diffusion area of the skin abutment surface side of the absorber 40 is small, the menstrual napkin 10C exhibits a whiteness superior to that of the menstrual napkin 10A.

As a second embodiment of the physiological product of the present invention, a liquid film-containing cracking agent region is provided on the front sheet 20, and a blood cell-containing material is provided on the chip material 42 on the skin abutment surface side of the absorbent core material 41. Menstrual tampons in the agglutinant area (hereinafter referred to as menstrual tampons 10D). In menstrual tampon 10D, the liquid film-containing cracking agent area of the front sheet 20 and the blood cell-containing agglutinating agent of the core material 42 The regions overlap at least partially and preferably all in plan view.

The menstrual tampon 10D has the same phenomenon as that of the menstrual tampon 10C, but there are differences in that no liquid film is formed not only on the core material 42 but also on the front sheet 20. Thereby, the whiteness of the front sheet 20 itself is improved compared with the menstrual tampon 10C, and therefore the shielding property of the red blood cell agglomerates in the absorber 40 is also improved. Results The surface whiteness of menstrual tampon 10D was better than that of menstrual tampon 10C.

In the physiological article of the present invention, the blood cell agglutinating agent and the liquid film cleaving agent may be arranged on any part of the absorbent body or on the skin abutting surface side than the absorbent body. Among them, in the case of being disposed on the absorbent body, it is preferable that each agent is disposed on the skin abutting surface side of the absorbent body or a chip material on the skin abutting surface side of the absorbent body. That is, it is preferable that each agent is disposed on the skin-contacting surface side of the higher absorbent polymer. Thereby, hemagglutination can be performed before blood is absorbed by the superabsorbent polymer. In addition, the surface tension of the blood can be reduced before the blood diffuses into the absorber.

In the physiological article of the present invention, the hemagglutinating agent-containing region is not disposed on the front sheet 20 but is disposed on the non-skin contact surface side of the front sheet, which is inside the physiological article. It is preferable to generate agglomerates of non-liquid components in menstrual blood typified by red blood cells and prevent the non-liquid components from adhering to the skin of the user. In the menstrual pads 10C and 10D, the blood cell agglutinating agent-containing regions are all disposed on the core material 42. The blood cell agglutinating agent-containing region may be disposed on the absorbent core material 41.

Moreover, in the physiological article of the present invention, in the thickness direction of the physiological article, the blood cell agglutinating agent-containing region and the liquid film-splitting agent-containing region can be arranged at the same position as menstrual cotton 10C, but it is easy to obtain From the viewpoint of the supplementary effect of the agent, it is preferable that the two regions are arranged at different positions, and it is particularly preferable that the region containing the liquid film-splitting agent, such as the menstrual tampon 10D, is disposed in the region containing hemagglutinating agent. Skin abuts face side. Furthermore, regarding the so-called "liquid-film-containing cracking agent zone" Compared to the state where the blood cell agglutinating agent-containing region is disposed on the skin abutting surface side, when the physiological product overlaps two regions in a plan view, as long as the overlapping portions are established with each other.

On the other hand, in the plane direction of the physiological article, the area containing the hemagglutinating agent and the area containing the liquid film lysing agent may not be spaced apart from each other, but from the viewpoint of easily obtaining the complementary effect of the two agents, it is preferably Menstrual tampons like 10C and 10D overlap in the plane direction.

In the case where the physiological article of the present invention is a menstrual tampon as shown in Figs. 5 and 6, the blood cell agglutinating agent-containing region and the liquid film cleaving agent-containing region are considered to make the two regions easily contact with blood. It is preferably provided in the abutment area of the excretory opening. The so-called excretory abutment area is the central part in the width direction and the length direction of the daily menstrual tampon, and the night period menstrual tampon is divided into four places along the length direction. The central portion of the width direction and the length direction of the divided area at the second position from the front side (the ventral side of the user).

The distribution pattern of the hemagglutinating agent in the plane direction in the region containing the hemagglutinating agent and the distribution pattern of the liquid film cleaving agent in the plane direction in the region containing the liquid film cleaving agent are not particularly limited, and any pattern may be used.

Taking the hemagglutinating agent-containing area as an example, for example, when the hemagglutinating agent-containing area is provided in the encapsulation material like the aforementioned menstrual pads 10C and 10D, the hemagglutinating agent can be continuously attached to the entire area of one side of the encapsulation material. Or, it may be continuously attached only to a part of one surface of the chip. The former form has the advantage of being able to cope with excretion from any location, and the latter form has the advantage of suppressing the decrease in the softness of the sheet due to the adhesion of the hemagglutinating agent. In addition, the adhesion pattern of the hemagglutination agent is not limited to the continuous adhesion pattern of the non-adhesion portion of such a hemagglutination agent, and may also be a discontinuous adhesion pattern in which the adhesion portion and the non-adhesion portion of the hemagglutination agent are mixed. Examples of the discontinuous adhesion pattern include: 1) a stripe pattern in which the adhesion portions of the hemagglutinating agent linear in a plan view are intermittently arranged in a direction orthogonal to the longitudinal direction thereof, and 2) they cross each other A plurality of lattice patterns formed on the adherence portion of the linear agglutination agent in a linear shape in a plan view, 3) a dot pattern in which the attachment portions of the blood agglutination agent in a specific shape such as a circle in a plan view are dispersedly arranged . The pattern of 1) described above has the advantage of allowing the excretory fluid to diffuse along the length of the attachment portion of the linear hemagglutination agent. For example, if the length direction of the attachment portion of the linear hemagglutination agent and the longitudinal direction of the physiological product (user Front-to-rear direction) will promote the diffusion of excretory fluid such as menstrual blood in the longitudinal direction. The patterns of 2) and 3) above all have the advantage of reducing the surface redness caused by the remaining red blood cell agglomerates, and the patterns of 2) also have the advantage of improving the certainty of the effect produced by the hemagglutinating agent. Regarding the area of the liquid film-containing cracking agent, the same agent attaching pattern as that of the area containing the hemagglutinating agent can also be used.

In the physiological article of the present invention, the area of the area containing the hemagglutinating agent and the area of the area containing the liquid film cleaving agent may be the same or different.

From the viewpoint of large-area contact with blood, the total area of the hemagglutinating agent-containing region in the physiological product is preferably 30 cm ² or more, more preferably 70 cm ² or more, and even more preferably 100 cm ² or more. In addition, the larger the total area of the hemagglutinating agent-containing region in the physiological article is, the better, but it is actually 350 cm ² or less.

From the viewpoint of large-area contact with blood, the total area of the liquid film-splitting agent-containing region in the physiological product is preferably 10 cm ² or more, more preferably 30 cm ² or more, and even more preferably 50 cm ² or more. In addition, the larger the total area of the liquid film-splitting agent-containing region in the menstrual cotton is, the better, but it is actually 350 cm ² or less.

(Analytical method)

A method for analyzing a blood agglutinating agent, a liquid film cleaving agent, and a third component from commercially available physiological products is as follows.

First, for the physiological products to be analyzed, a heating device such as a dryer is used to make the structures After the hot-melt adhesive of the piece is weakened, it is decomposed into components such as a front sheet, an absorber, and a back sheet. Then, the decomposed members are subjected to a multi-stage solvent extraction method from a non-polar solvent to a polar solvent, the solvent is dried, and the mixture to be measured is taken out. After selecting a suitable column and a solvent according to the composition of the extracted substance, each component is separated by high performance liquid chromatography, and then each component is subjected to NMR (nuclear magnetic resonance method), IR (infrared spectroscopy), and MS. (Mass spectrometry), elemental analysis, etc., thereby identifying the structure of each component. At the same time, the weight of each component was measured. When a polymer compound is included, it is easier to identify the constituents by using a method such as gel permeation chromatography (GPC) in combination.

In the case where the amount of the obtained constituent components is insufficient to supply each measurement, if the substance is a commercially available product, a sufficient amount is obtained by synthesizing it if it is not a commercially available product.

Accordingly, when the obtained constituent component is a cationic polymer, or when it is a substance having the above-mentioned (the property of forming an agglomerate), it is judged as a blood cell agglutinating agent. In addition, when the expansion coefficient of the obtained constituent component to a liquid having a surface tension of 50 mN / m is 15 mN / m or more, or to a liquid having a surface tension of 50 mN / m, the expansion coefficient is greater than 0 mN / m and the surface tension is When the interfacial tension of a liquid that is 50 mN / m is 20 mN / m or less, or when it has a substance that has the above-mentioned property to make the liquid film disappear, it is judged as a liquid film cracking agent. Those who are neither a hemagglutinating agent nor a liquid film cracking agent are judged to be the third component.

(Determination of molecular weight)

The molecular weight of the cationic polymer (hemagglutinating agent) can be measured using HLC-8320GPC manufactured by Tosoh Corporation. Specific measurement conditions are as follows.

In the case of a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate

Separation column: Connector for α-M tandem connection of protection column α and analysis column (manufactured by Tosoh Co., Ltd.)

Eluent: 150 mmol / L sodium sulfate and 1% by mass acetic acid dissolved in water

Solvent flow rate: 1.0ml / min

Injection volume: 100 μL

Separation column temperature: 40 ° C

Cases other than copolymers containing water-soluble polymerizable monomers such as hydroxyethyl methacrylate

Separation column: Connector for α-M tandem connection of protection column α and analysis column (manufactured by Tosoh Co., Ltd.)

Eluent: 50 mmol / L lithium bromide and 1% by mass of acetic acid dissolved in ethanol: water = 3: 7 (volume ratio)

Solvent flow rate: 0.6ml / min

Injection volume: 100 μL

Separation column temperature: 40 ° C

The detector uses RI (refractive index). As a measurement sample, 1 mg of the cationic polymer to be measured was dissolved in 1 mL of the eluent. For copolymers containing water-soluble polymerizable monomers such as hydroxyethyl methacrylate, amylopectin with a molecular weight of 5900, amylopectin with a molecular weight of 47300, amylopectin with a molecular weight of 212,000, and amylopectin with a molecular weight of 788,000 2.5 mg each of the amylopectin mixture obtained by dissolving in 10 mL of the eluate was used as the molecular weight standard. For copolymers containing water-soluble polymerizable monomers such as hydroxyethyl methacrylate, polyethylene glycol (PEG) with a molecular weight of 106, PEG with a molecular weight of 400, PEG with a molecular weight of 1470, PEG with a molecular weight of 6,450, and a molecular weight of 5 are used. Polyethylene oxide (PEO) of 10,000, PEO with a molecular weight of 235,000, and PEO with a molecular weight of 875,000 were each dissolved in 20 mL of a PEG-PEO mixture as a molecular weight standard.

The weight average molecular weight of a polymer compound other than the cationic polymer is measured using a gel permeation chromatography (GPC) "CCPD" (trade name, manufactured by Tosoh Corporation). The measurement conditions are as follows. The calculation of the converted molecular weight was performed based on polystyrene.

Separation column: GMHHR-H + GMHHR-H (cation)

Eluent: L Farmin DM20 / CHCl3

Solvent flow rate: 1.0ml / min

Separation column temperature: 40 ° C

(Water solubility)

In the present specification, the "water solubility" refers to a mass capable of dissolving a hemagglutinating agent or a liquid film cleaving agent in 100 g of deionized water. In addition, the "water-soluble" in this specification means the thing whose water solubility is 10 g or more.

In an environmental area with a temperature of 25 ° C and a relative humidity (RH) of 65%, while stirring 100 g of deionized water with a stirrer, the compound to be measured was slowly dissolved, and the degree of dissolution was visually observed, and the compound was no longer dissolved. The solubility of the compound at the time point, that is, the time point at which any of suspension, precipitation, precipitation, and white turbidity can be visually confirmed, is set to water solubility. Specifically, it measured by adding 0.0001 g of agents each time. As a result, those who could not dissolve even 0.0001 g were recorded as "less than 0.0001 g", and those who could dissolve 0.0001 g but failed to dissolve 0.0002 g were described as "0.0001 g". In addition, when the compound to be measured is a surfactant, the so-called "dissolved" means both monodisperse dissolution and microcell dissolution dissolution. The amount of dissolution at the time point of suspension or precipitation, precipitation, and turbidity is observed. Is water solubility.

(Production method)

The hemagglutinating agent-containing region and the liquid-film-splitting agent region can be impregnated with a separate component of the agent or a solution containing the above agent by making synthetic fibers constituting a non-woven fabric, pulp fibers constituting an absorbent body, or a superabsorbent polymer in advance. Later, it is formed by producing menstrual tampons. In addition, non-woven synthetic fibers can also be used. Non-woven fabrics can be formed. Pulp fibers can be formed into absorbent core materials or core-coated materials. These absorbent core materials or core-coated materials are coated with these agents alone or contained. Above Method of solution. Examples of the solution include a solution obtained by diluting a hemagglutinating agent or a liquid film cleaving agent with a solvent (hereinafter, this solution is also referred to as an agent solution). Furthermore, the above-mentioned phosphate ester type anionic surfactant may be mixed in a solution containing a liquid film cleaving agent. In this case, the content ratio of the liquid film cleaving agent and the phosphate-type anionic surfactant is preferably as described above. As the said solvent, those who can dissolve or disperse | distribute these agents suitably in a solvent, and can apply | coat easily can be used without a restriction | limiting in particular. For example, examples of a person who dissolves a hemagglutinating agent include alcohols such as ethanol and methanol, and water. For dissolving the liquid film cracking agent, organic solvents such as ethanol, methanol, acetone, and hexane can be used, or when an emulsion is prepared, of course, water can be used as a solvent or a dispersion medium for emulsification. Examples of the emulsifier used include various surfactants including alkyl phosphate, fatty acid ammonium, alkyl betaine, sodium alkyl sulfosuccinate, and the like. Examples of the solvent that dissolves the hemagglutinating agent and the liquid film cleaving agent at the same time include a mixed solvent of water and alcohol.

As a method for attaching the blood cell agglutinating agent and the liquid film cleaving agent to the surface of the constituent material, various methods generally used can be adopted without particular limitation. Examples include coating by a sprayer, coating by a slot coater, dipping, and the like. When the agents are applied to a non-woven fabric, these treatments may be performed on the fibers before the webbing, or after the fibers are webbed by various methods. In the case where the agents are applied to an absorbent body, these treatments may be performed on fluff pulp or an absorbent polymer before being formed into the shape of the absorbent body, or may be applied to the absorbent core after being formed into the shape of the absorbent body. Wood or encapsulation. In addition, if necessary, a solution of the agent in which these agents are dissolved in a solvent, or an emulsion or dispersion of these agents is used. In this case, it is preferable that the constituent material having the agents adhered to the surface be dried at a temperature sufficiently lower than the melting point or ignition point of the constituent material (for example, 120 ° C. or lower) using, for example, a hot-air blower dryer.

The physiological products of the present invention are not limited to menstrual tampons, but can also be applied to other physiological products such as sanitary pads as long as there is a possibility of absorbing blood.

About the said embodiment, this invention further discloses the following aspect.

<1>

A physiological article includes a front sheet on the skin abutting surface side, a back sheet on a non-skin abutting surface side, and an absorbent body sandwiched therebetween, and is absorbed in the absorbent body or above. The blood cell agglutinating agent-containing region containing the blood cell agglutinating agent and the liquid film cleaving agent region containing the liquid film cleaving agent are arranged closer to the skin abutting surface side.

<2>

The physiological article according to the above <1>, wherein the hemagglutinating agent is a cationic polymer.

<3>

The physiological article according to the above <1> or <2>, wherein the expansion coefficient of the liquid film cleaving agent to a liquid having a surface tension of 50 mN / m is 15 mN / m or more.

<4>

A physiological article includes a front sheet on the skin abutting surface side, a back sheet on a non-skin abutting surface side, and an absorbent body sandwiched therebetween, and is absorbed in the absorbent body or above. The cationic polymer-containing region containing the cationic polymer and the compound-containing region containing the following compound C1 are arranged closer to the skin abutting surface side.

[Compound C1]

Compounds with an expansion coefficient of 15 mN / m or more for liquids with a surface tension of 50 mN / m.

<5>

The physiological article according to any one of the above <1> to <4>, wherein the liquid film cracking agent Or the expansion coefficient of the above compound C1 to a liquid having a surface tension of 50 mN / m is 15 mN / m or more, preferably 20 mN / m or more, more preferably 25 mN / m or more, and further preferably 30 mN / m or more. 50mN / m or less.

<6>

The physiological article according to any one of the above <1> to <5>, wherein the liquid film cleaving agent or the compound C1 includes at least one structure selected from the group consisting of the following structures X, XY, and YXY compound of.

Structure X represents> C (A)-<C represents a carbon atom. In addition, <,>, and-represent a bond key. Same as below>, -C (A) _2- , -C (A) (B)-,> C (A) -C (R ¹ ) <,> C (R ¹ )-, -C (R ¹ ) ( R ² )-, -C (R ¹ ) ₂ -,> C <, and -Si (R ¹ ) ₂ O-, -Si (R ¹ ) (R ² ) O- repeat any of the basic structures or A combination of two or more types of siloxane chain structure or a mixed chain thereof. The structure X has a terminal selected from a hydrogen atom, or -C (A) ₃ , -C (A) ₂ B, -C (A) (B) ₂ , -C (A) ₂ -C (R ¹ ) ₃ , -C (R ¹ ) ₂ A, -C (R ¹ ) ₃ , or -OSi (R ¹ ) ₃ , -OSi (R ¹ ) ₂ (R ² ), -Si (R ¹ ) ₃ , -Si ( At least one kind of group in the group consisting of R ¹ ) ₂ (R ² ).

The R ¹ or R ² each independently represents a hydrogen atom, an alkyl group, an alkoxy group, an aryl group, or a halogen atom. A and B each independently represent a substituent containing an oxygen atom or a nitrogen atom. When there are a plurality of R ¹ , R ² , A, and B in the structure X, these may be the same as or different from each other.

Y represents a hydrophilic group containing an atom selected from a hydrogen atom, a carbon atom, an oxygen atom, a nitrogen atom, a phosphorus atom, and a sulfur atom and having hydrophilicity. When Y is plural, they may be the same as or different from each other.

<7>

The physiological article according to any one of the above <1> to <6>, wherein the liquid film cleaving agent or the compound C1 is an organically modified polysiloxane, and the organic modification is selected from the group consisting of amine-modified, epoxy change Properties, carboxyl modification, glycol modification, methanol (carbinol) modification, (meth) acrylic acid modification, thiol modification, phenol modification, polyether modification (including polyoxyalkylene modification) , One or more of methyl styryl modification, long chain alkyl modification, higher fatty acid ester modification, higher alkoxy modification, higher fatty acid modification or fluorine modification.

<8>

The physiological article according to any one of the above <1> to <6>, wherein the liquid film cleaving agent or the compound C1 is a polyoxyalkylene modified polymer represented by the following formulas [I] to [IV] Silicone.

[Chemical 24]

<9>

The physiological article according to the above <1> or <2>, wherein the expansion coefficient of the liquid film cracking agent to a liquid having a surface tension of 50 mN / m is greater than 0 mN / m, and the liquid film cracking agent has a surface tension of 50 mN / m The interfacial tension of the liquid is below 20 mN / m.

<10>

A physiological article includes a front sheet on the skin abutting surface side, a back sheet on a non-skin abutting surface side, and an absorbent body sandwiched therebetween, and is absorbed in the absorbent body or above. The cationic polymer-containing region containing the cationic polymer and the compound-containing region containing the following compound C2 are arranged closer to the skin abutting surface side.

[Compound C2]

Compounds whose expansion coefficient is greater than 0 mN / m for liquids with a surface tension of 50 mN / m, and whose interfacial tension is 20 mN / m or less for liquids with a surface tension of 50 mN / m.

<11>

The physiological article as described in the above <1>, <2>, <9>, or <10>, wherein the expansion coefficient of the liquid film cracking agent or the compound C2 to a liquid having a surface tension of 50 mN / m is greater than 0 mN / m, which is more than It is preferably 9 mN / m or more, more preferably 10 mN / m or more, still more preferably 15 mN / m or more, and 50 mN / m or less.

<12>

The physiological article according to any one of the above <1>, <2>, <9> to <11>, wherein the liquid film cleaving agent or the compound C2 includes a compound selected from the group consisting of the following structures Z, ZY, and YZY A compound of at least one structure in the group.

Structure Z represents> C (A)-<C: carbon atom>, -C (A) _2- , -C (A) (B)-,> C (A) -C (R ³ ) <,> C ( R ³ )-, -C (R ³ ) (R ⁴ )-, -C (R ³ ) ₂ -,> C <Any of the basic structures in which the basic structure is repeated or a combination of two or more structures . At the end of structure Z has a member selected from the group consisting of a hydrogen atom, or -C (A) ₃ , -C (A) ₂ B, -C (A) (B) _2, -C (A) ₂ -C (R ³ ) ₃ At least one type of group consisting of -C (R ³ ) ₂ A, -C (R ³ ) ₃ .

The R ³ or R ⁴ each independently represent a hydrogen atom, an alkyl group, an alkoxy group, an aryl group, a fluoroalkyl group, an aralkyl group, or a hydrocarbon group or a fluorine atom in combination of these. A and B each independently represent a substituent containing an oxygen atom or a nitrogen atom.

Y represents a hydrophilic group containing an atom selected from a hydrogen atom, a carbon atom, an oxygen atom, a nitrogen atom, a phosphorus atom, and a sulfur atom and having hydrophilicity. When Y is plural, they may be the same as or different from each other.

<13>

The physiological article according to any one of the above <1>, <2>, <9> to <12>, wherein the liquid film cleaving agent or the compound C2 is any one selected from the following formula [V] The polyoxyalkylene alkyl (POA) ether represented, or a polyoxyalkylene glycol having a mass average molecular weight of 1000 or more, represented by the following formula [VI], stearyl polyether, behenyl polyether , One or more of PPG myristyl ether, PPG stearyl ether, or PPG behenyl ether.

[Chemical 25]

<14>

The physiological article according to any one of <1>, <2>, and <9> to <12>, wherein the liquid film cleaving agent or the compound C2 is a fatty acid selected from the group consisting of the following formula [VII], Any one of the glycerin fatty acid ester or pentaerythritol fatty acid ester represented by the following formula [VIII-I] or [VIII-II], the following formula [IX], the following formula [X], or the following formula [XI] Glycerol fatty acid esters, sorbitan fatty acid esters, or partial esterified products of pentaerythritol fatty acid esters represented by one, sterols represented by the following formula [XII], alcohols represented by the following formula [XIII], One or more types of the fatty acid ester represented by the following formula [XIV] or the wax represented by the following formula [XV].

[Formula _{27] C m H n -COOH [} VII]

[Chemical 28]

[Formula _{34] C m H n -OH [} XIII]

[Formula _{35] C m H n -COO-} C m H n [XIV]

[Chem. 36] C _m H _n [XV]

<15>

The physiological article according to any one of the above <1> to <14>, wherein the melting point of the liquid film cleaving agent or the compound C1 or the compound C2 is preferably 40 ° C or lower, more preferably 35 ° C or lower, and The temperature is preferably -220 ° C or higher, and more preferably -180 ° C or higher.

<16>

The physiological article according to any one of the above-mentioned <1> to <15>, wherein the water-solubility of the liquid film cracking agent or the compound C1 or the compound C2 is 0 g or more, preferably 1.0 × 10 ^-9 g or more, It is 0.025 g or less, preferably 0.0017 g or less, and more preferably 0.0001 g or less.

<17>

The physiological article according to any one of the above <1> to <16>, wherein the interfacial tension of the liquid film cracking agent or the compound C1 or the compound C2 on a liquid having a surface tension of 50 mN / m is preferably 20 mN / m Below, more preferably 17 mN / m or less, still more preferably 13 mN / m or less, even more preferably 10 mN / m or less, even more preferably 9 mN / m or less, most preferably 1 mN / m or less, and more than 0 mN / m .

<18>

The physiological article according to any one of the above <1> to <17>, wherein the surface tension of the liquid film cracking agent or the compound C1 or the compound C2 is preferably 32 mN / m or less, more preferably It is 30 mN / m or less, more preferably 25 mN / m or less, particularly preferably 22 mN / m or less, and further preferably 1 mN / m or more.

<19>

The physiological article according to any one of the above <1> to <18>, wherein the weight average molecular weight of the liquid film cleaving agent or the compound C1 or the compound C2 is preferably 500 or more, more preferably 1,000 or more, and more preferably It is preferably 1500 or more, particularly preferably 2,000 or more, and more preferably 50,000 or less, more preferably 20,000 or less, and even more preferably 10,000 or less.

<20>

The physiological article according to any one of the above <1> to <19>, wherein the hemagglutinating agent or the cationic polymer is a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer, or a quaternary ammonium salt polycondensation Thing.

<21>

The physiological article according to any one of the above <1> to <20>, wherein the weight-average molecular weight of the hemagglutination agent or the cationic polymer is preferably 2,000 or more, more preferably 10,000 or more, and even more preferably More than 30,000, more preferably 10 million or less, more preferably 5 million or less, still more preferably 3 million or less.

<22>

The physiological article according to any one of the above <1> to <21>, wherein the hemagglutinating agent or the cationic polymer has a structure including a main chain and a side chain bonded to the main chain, and has the following A quaternary ammonium salt homopolymer of a repeating unit represented by Formula 1, or a structure including a main chain and a side chain bonded to the main chain, and having a repeating unit represented by Formula 1 below and Formula 2 below In the quaternary ammonium salt copolymer of the repeating unit shown, the main chain and the side chain of the hemagglutination agent or the cationic polymer are bonded at one point, and the side chain has a quaternary ammonium site.

<23>

The physiological article according to any one of the above <1> to <22>, wherein the hemagglutinating agent or the cationic polymer is a quaternary ammonium salt-containing homopolymer or a quaternary ammonium salt having a flow potential of 1500 μeq / L or more Copolymer water-soluble cationic polymer.

<24>

The physiological article according to any one of the above <1> to <23>, wherein the agglutination speed of the blood cell agglutinating agent or the cationic polymer is 0.75 mPa · s / s or less.

<25>

The physiological article according to any one of the above <1> to <24>, wherein the value of the inorganic value / organic value as a ratio of the inorganic value to the organic value of the blood cell agglutinating agent or the cationic polymer It is 0.6 or more and 4.6 or less, and the hemagglutinating agent or the cationic polymer is a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer, or a quaternary ammonium salt polycondensate.

<26>

The physiological article according to any one of the above <1> to <25>, wherein the absorbent body comprises a superabsorbent polymer.

<27>

The physiological article according to any one of the above <1> to <26>, wherein the absorbent body has a fiber accumulation body in which a short fiber pulp and a superabsorbent polymer are mixed.

<28>

The physiological article according to the above <26> or <27>, wherein the hemagglutinating agent-containing region or the cationic polymer-containing region and the liquid-film-splitting agent-containing region or the compound-containing region are disposed at higher absorption than the above Sexual polymer is closer to the side of the skin.

<29>

The physiological article according to any one of the above <1> to <28>, wherein the blood cell agglutinating agent-containing region or the cationic polymer-containing region is disposed closer to the non-skin abutting surface side than the front sheet. .

<30>

The physiological article according to any one of the above <1> to <29>, wherein the liquid-film-containing cleaving agent region or the compound-containing region is disposed more than the blood cell agglutinating agent region or the cationic polymer-containing region. Lean closer to the skin.

<31>

The physiological article according to any one of the above <1> to <30>, wherein the liquid-film-containing cleaving agent region or the compound-containing region and the hemagglutinating agent-containing region or the cationic polymer-containing region are in a plane direction overlapping.

<32>

The physiological article according to any one of the above-mentioned <1> to <31>, wherein the liquid-film-containing cracking agent region or the compound-containing region is disposed on the front sheet.

<33>

The physiological article according to any one of the above <1> to <32>, wherein the absorbent body has an absorbent core material and a core-coated material covering the absorbent core material.

<34>

The physiological article according to the above <33>, wherein the encapsulating material or the cationic polymer-containing region is disposed on the core material on the skin abutment surface side of the absorbent core material.

<35>

The physiological article according to any one of the above-mentioned <1> to <34>, wherein the blood-containing clot One or both of the collector region, the cationic polymer-containing region, the liquid-film-containing cleaving agent region, or the compound-containing region are disposed in the excretory abutment region of the physiological article.

[Example]

Hereinafter, the present invention will be described more specifically with reference to examples, but the present invention is not limited to these examples. The expansion coefficient, the interfacial tension, the surface tension, and the water solubility were measured as described above in an environmental region of a temperature of 25 ° C. and a relative humidity (RH) of 65%. The flow potential and IOB value of the hemagglutinating agent, and the surface tension, water solubility, and interfacial tension of the liquid film cleaving agent in the following examples were measured or calculated by the above-mentioned measurement method or calculation method. In addition, "-" in the following table means that the agent indicated by the item name is not used, does not have a value equivalent to the item, and the like. The OPU of the liquid film cracking agent is a content ratio with respect to the fiber mass of the entire nonwoven fabric.

[Example 1]

A menstrual tampon having the same structure as that of the menstrual tampon 10 shown in FIG. 5 was produced according to a conventional method. Specifically, for a commercially available menstrual tampon ("LAURIER HADA-KIREI Guard Daily Common Wing Type" produced by Kao Co., Ltd. in 2015), the hot-melt adhesive that adheres to each component is weakened by a dryer. Use each of the front sheet, back sheet, and absorber that have been disassembled. This absorbent system is obtained by covering an absorbent core material containing a mixed fiber stack of a short fiber pulp and a superabsorbent polymer with a core material (hereinafter also referred to as an absorbent X).

The entire encapsulation material (skin-side encapsulation material) located on the skin abutment surface side of the absorber X is coated with diallyldimethylammonium chloride (Merquat 100, manufactured by Lubrizol Japan Co., Ltd.) (hereinafter also Called Agent A) as a hemagglutinating agent, and then coated with polyoxyethylene (POE) modified dimethylpolysiloxane (manufactured by Shin-Etsu Chemical Co., Ltd., KF-6015) (hereinafter also referred to as Agent G) as a liquid Membrane cracking agent. The specific coating methods of the two agents are described below.

In this way, the whole area of the skin-side enveloping material forming the skin-opposing surface is superimposed with blood cell agglutination. The absorbent body X of the agent and the liquid film cleaving agent overlaps the front sheet on the skin-facing side of the skin, and applies pressure to integrate the two, and further superimposes the back sheet on the non-skin facing surface of the absorber X to obtain The menstrual tampon of Example 1.

The coating method of the agent A in Example 1 is as follows. The agent A was dissolved in the solvent ethanol to prepare a 0.06 mass% dilution liquid as a coating liquid, and the coating liquid was applied to the entire area of the skin abutment surface of the skin-side coated core material of the absorber X with a sprayer, and then the solvent was applied. dry.

The coating method of the agent G in Example 1 is as follows. The agent G was dissolved in a solvent ethanol to prepare a diluent of 0.06% by mass of the active ingredient of the liquid film cleaving agent as a coating liquid, and the coating was applied to the entire area of the skin abutment surface of the skin side of the absorbent body X by using a sprayer. The cloth was dried, and then the solvent was dried. Regarding the agent G, X in the above structure XY contains a dimethylpolysiloxane chain containing -Si (CH ₃ ) ₂ O-, Y contains a POE chain containing-(C ₂ H ₄ O)-, and the end of the POE chain The group is methyl (CH ₃ ), the modification ratio is 20%, and the polyoxyethylene addition mole number is 3.

When measuring the expansion coefficient and interfacial tension of the polyoxyethylene (POE) -modified dimethylpolysiloxane, a "liquid with a surface tension of 50 mN / m" was obtained using a micropipette (ACURA825, Socorex Isba SA). (Manufactured) Polyoxyethylene sorbitan monolaurate (manufactured by Kao Corporation, trade name RHEODOL SUPER TW-L120) was added to 100 g of deionized water as a nonionic surface active substance to adjust the surface tension. It is a solution of 50 ± 1mN / m.

[Example 2]

The menstrual tampon of Example 2 was obtained in the same manner as in Example 1 except that the coating solution of the liquid film cleaving agent was applied to the front sheet instead of the core material (absorber).

[Examples 3 to 7]

Except that the hemagglutinating agent was changed to the following agents B to F, the same procedure as in Example 1 was performed except that The menstrual tampons of Examples 3 to 7 were obtained in a manner.

‧Drug B (Example 3): diallyldimethylammonium chloride (manufactured by Nittobo Medical Co., Ltd., PAS-H-5L)

‧Drug C (Example 4): Polymethacryloxyethyldimethylammonium diethyl sulfate (the diethyl sulfate of dimethylaminoethyl methacrylate was dissolved as a solvent Ethanol, 2,2'-Azobis (2-methylpropionamidine) dihydrochloride (2,2'-azobis (2-methylpropane) dihydrochloride) as an oil-soluble azo initiator (Wako Pure Chemical Industries, Ltd.) V-65B manufactured by Co., Ltd.) and heated to polymerize to obtain a water-soluble quaternary ammonium salt homopolymer)

‧Dose D (Example 5): polymethacryloxyethyldimethylammonium diethylsulfate / dimethylacrylamide copolymer (the former / the latter = 56: 44 Molar ratio use Diethyl sulfate of dimethylaminoethyl methacrylate and dimethylacrylamide are dissolved in ethanol as a solvent, and 2,2'-Azobis (as an oil-soluble azo initiator is added) 2-methylpropionamidine) dihydrochloride (V-65B manufactured by Wako Pure Chemical Industries, Ltd.) and heating to copolymerize it to obtain a water-soluble quaternary ammonium salt copolymer)

‧Dose E (Example 6): polymethacryloxyethyltrimethylammonium sulfate (manufactured by SENKA)

‧Factor F (Example 7): Polymethacryloxyethyltrimethylammonium methyl hydrochloride (dissolving the chlorinated methyl salt of dimethylaminoethyl methacrylate in a solvent Ethanol, 2,2'-Azobis (2-methylpropionamidine) dihydrochloride (V-65B manufactured by Wako Pure Chemical Industries, Ltd.) as an oil-soluble azo initiator is added, and it is heated to polymerize to obtain water-soluble Quaternary ammonium homopolymer Thing)

[Examples 8 to 9]

The menstrual napkins of Examples 8 to 9 were obtained in the same manner as in Example 1 except that the liquid film cracking agent was changed to the following agents H to I.

‧Agent H (Example 8): Polyoxypropylene (POP) alkyl ether (manufactured by Kao Corporation, defoamer No. 8)

‧Drug I (Example 9): Trioctanoic acid‧Glyceryl caprylate (manufactured by Kao Corporation, COCONARD MT)

[Example 10]

For commercially available menstrual tampons ("Laurier Slim Guard Daily-Use Reinforced Wing Type 25cm" produced by Kao Corporation in 2015), use a dryer to weaken the hot-melt adhesive that adheres to each component. Each of a front sheet, a back sheet, and an absorber. This absorbent system is obtained by covering an absorbent core material (hereinafter also referred to as an absorber Y) composed of five sheets of superabsorbent polymer sandwiched between two sheets of corrugated paper with a core material. Except for the above, a menstrual tampon of Example 10 was obtained in the same manner as in Example 1.

[Reference Example 1]

A menstrual tampon of Reference Example 1 was obtained in the same manner as in Example 1 except that the liquid film cleaving agent was not applied.

[Reference Example 2]

A menstrual tampon of Reference Example 2 was obtained in the same manner as in Example 1 except that no hemagglutination agent was applied.

[Reference Example 3]

A reference was obtained in the same manner as in Example 10 except that the liquid film cracking agent was not applied. The menstrual tampon of Example 3.

[Reference Example 4]

A menstrual tampon of Reference Example 4 was obtained in the same manner as in Example 10 except that no hemagglutination agent was applied.

[Comparative Example 1]

The commercially available menstrual tampons (`` LAURIER HADA-KIREI Guard Daily Common Wing Types '' produced by Kao Corporation in 2015), that is, menstrual periods that do not contain hemagglutinating agents and do not contain liquid film dehiscants The tampon was used as the menstrual tampon of Comparative Example 1.

With respect to the above examples, reference examples, and comparative examples, the amounts of liquid return, diffusion area, and surface whiteness (L value) were evaluated by the following methods, respectively. The results are shown in Tables 2 to 5 below.

<Evaluation method of liquid return amount>

The subject's menstrual napkins were unfolded into a flat shape and placed horizontally with the skin-facing side (front sheet side) facing up. The inner diameter of the tube was 22 mm. The cylindrical part made of acrylic resin with a height of 50mm is located at 10mm The liquid injection plate made of acrylic resin is integrally formed with the opening for liquid injection. The liquid injection hole is located in the center of the area facing the excretion portion in the skin-facing surface (front sheet side) of the menstrual napkin. The method is stacked on the sanitary napkin, and a weight (including the liquid injection plate itself) is appropriately placed to adjust the load to 5 g / m ² . 3g of the above-mentioned simulated blood was weighed and placed in a 10cc injection beaker. The blood was quickly injected into the cylinder of the liquid injection plate at one time, and then left for 3 minutes, and then 3 g was injected again, and the menstrual napkin was left in this state for 3 minutes. Immediately after, put 10 pieces of weighed absorbent paper (Advantec 5A, 55mm) on the blood-filled part of the sanitary napkin. ) And a cuboid weight of 960 g, let stand for 10 seconds, and calculate the amount of blood (g) absorbed by the absorbent paper based on the weight of the absorbent paper after 10 seconds. The measurement was performed 3 times, and the average value was taken as the liquid return amount of the menstrual tampon. The smaller the amount of liquid return, the better the absorption performance of the menstrual cotton.

<Evaluation method of diffusion area>

After the menstrual tampon is removed from the front sheet, etc. immediately after the above <Evaluation Method of Liquid Return Amount>, an OHP sheet is superposed on the skin-contacting surface side and non-skin-contacting surface side of the absorber (KOKUYO Co., Ltd. , Regenerated OHP film, A4 size, VF-1300N transparent), trace out the wetting range. Thereafter, the OHP sheet was read with a scanner, and taken into an image software (manufactured by Nippon Roper Co., Ltd., Image-Pro 6.2J) to calculate the area. The measurement was performed three times, and the average value was taken as each diffusion area.

The ratio of the diffusion area on the non-skin abutting surface side of the absorbent body to the diffusion area on the skin abutting surface side of the absorbent body was calculated (the latter / the former). When the ratio exceeds 1, that is, when the diffusion area on the non-skin contact surface side is larger than the diffusion area on the skin contact surface side, it means that the blood (the above-mentioned simulated blood) is in the absorber from the skin contact surface side When it moves to the non-skin contact surface side, it spreads in the planar direction, and the ratio becomes larger as it exceeds 1, meaning that the diffusion is promoted. Further, if the diffusion of the blood is promoted, for a user who sees the skin abutment surface side of a physiological article after use, the blood remaining on the skin abutment surface side is in phase with the non-skin abutment surface side. The ratio is relatively small, so it may be related to the trust in the absorption performance of the physiological product, the peace of mind, and it may also be related to the improvement of the surface whiteness after use. That is, the larger the ratio, the higher the evaluation.

<Evaluation method of surface whiteness (L value)>

A color difference meter (SPECTRO PHOTOMETER NF333, manufactured by Nippon Denshoku Industries Co., Ltd.) was placed on the front sheet of the menstrual napkin immediately after the above <Evaluation Method of the Amount of Liquid Returned>. The injection site was measured. Three measurements were performed, and the average value was taken as the L value. A larger L value indicates better surface whiteness after use.

[Table 2] [table 3] [Table 4] [table 5] As shown in Tables 2 to 4, since Examples 1 to 9 contained the two agents of a blood cell agglutinating agent and a liquid film cleaving agent, the liquid return amount was 1/10 or less of that of Comparative Example 1. Since Example 1 contains the two components of a blood agglutinating agent and a liquid film cracking agent, compared with Reference Example 1 and Reference Example 2 containing only one agent, the liquid return amount is less than 1/5, and the L value is greater than that of Reference Example 1. Excellent whiteness. In addition, since Examples 2 to 9 had a liquid film cleaving agent on the front sheet, the L value was larger than that of Comparative Example 1 or Reference Example 1, and the whiteness was very excellent. In addition, as shown in Table 5, Example 10 which changed the absorbent body from absorbent body X to absorbent body Y and contained a blood cell agglutinating agent and a liquid film cleaving agent was compared with Reference Example 3 and Reference which contained only one agent. Example 4, the amount of liquid returned is small, and the L value is large. [Industrial Applicability] The physiological product of the present invention has a small amount of liquid return and excellent surface whiteness after use.

Claims (14)

A physiological article comprising a front sheet on the skin abutting surface side, a back sheet on a non-skin abutting surface side, and an absorbent body sandwiched therebetween, in the absorbent body or above the absorbent body. A blood agglutinating agent-containing region containing a blood agglutinating agent and a liquid film-splitting agent region containing a liquid film-splitting agent are further arranged on the skin abutting surface side. The liquid film-splitting agent has a surface tension of 50 mN / m for a liquid The expansion coefficient is greater than 0 mN / m, and the interfacial tension of the liquid film cracking agent on a liquid having a surface tension of 50 mN / m is 20 mN / m or less. The physiological article according to claim 1, wherein the hemagglutinating agent is a cationic polymer. For example, the physiological article of claim 1 or 2, wherein the expansion coefficient of the liquid film cleaving agent to a liquid having a surface tension of 50 mN / m is 15 mN / m or more. A physiological article includes a front sheet on the skin abutting surface side, a back sheet on a non-skin abutting surface side, and an absorbent body sandwiched therebetween, and is absorbed in the absorbent body or above. The cationic polymer-containing region containing the cationic polymer and the compound-containing region containing the following compound C1 are arranged closer to the skin abutting surface side. [Compound C1] expands to a liquid having a surface tension of 50 mN / m. Compounds with a coefficient of 15 mN / m or more. A physiological article includes a front sheet on the skin abutting surface side, a back sheet on a non-skin abutting surface side, and an absorbent body sandwiched therebetween, and is absorbed in the absorbent body or above. The cationic polymer-containing region containing the cationic polymer and the compound-containing region containing the following compound C2 are arranged closer to the skin abutting surface side. [Compound C2] expands to a liquid having a surface tension of 50 mN / m. Compounds with a coefficient greater than 0 mN / m and an interfacial tension to a liquid with a surface tension of 50 mN / m is 20 mN / m or less. The physiological article according to any one of claims 1, 4 and 5, wherein the water solubility of the liquid film cracking agent or the compound C1 or the compound C2 is 0 g or more and 0.025 g or less. The physiological article according to any one of claims 1, 4, and 5, wherein the hemagglutinating agent or the cationic polymer is a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer, or a quaternary ammonium salt polycondensate. The physiological article according to any one of claims 1, 4 and 5, wherein the agglutination speed of the blood cell agglutinating agent or the cationic polymer is 0.75 mPa · s / s or less. The physiological article according to any one of claims 1, 4, and 5, wherein the absorbent body comprises a superabsorbent polymer. The physiological article according to claim 9, wherein the hemagglutinating agent-containing region or the cationic polymer-containing region and the liquid film cleaving agent region or the compound-containing region are arranged closer to the skin than the superabsorbent polymer. Junction side. The physiological article according to any one of claims 1, 4, and 5, wherein the blood cell agglutinating agent-containing region or the cationic polymer-containing region is disposed closer to the non-skin abutting surface side than the front sheet. The physiological article according to any one of claims 1, 4, and 5, wherein the liquid-film-containing cracking agent region or the compound-containing region is disposed closer to the blood cell agglutinating agent region or the cationic polymer-containing region. Skin abuts face side. The physiological article according to any one of claims 1, 4, and 5, wherein the liquid-film-containing cleavage agent region or the compound-containing region and the hemagglutinating agent-containing region or the cationic polymer-containing region overlap in a planar direction. The physiological article according to any one of claims 1, 4, and 5, wherein the liquid-film-containing cracking agent region or the compound-containing region is disposed on the front sheet.